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1. 	Abstract		
	
The	 European	 commission	 defines	 personalised	medicine	 as	 a	medical	 approach	
that	uses	molecular	insights	into	health	and	disease	brought	on	by	the	sequencing	of	
the	 genome	 to	 guide	 decision-making	 with	 regard	 to	 the	 prediction,	 prevention,	
diagnosis	 and	 treatment	 of	 illnesses.	 Its	main	 aim	 is	 generally	 perceived	 to	 be	 “the	
right	treatment	for	the	right	person	at	the	right	time”.	
	
This	new	approach	to	medicine	attracted	worldwide	attention	in	2012	when	president	
Obama	 launched	 a	 research	 project	 with	 the	 objective	 to	 implement	 personalised	
medicine	principles	in	America.	On	his	speech,	he	used	Ivacaftor	as	an	example	of	the	
potential	of	personalised	medicine.	The	importance	of	 Ivacaftor	development	 lays	on	
the	fact	that	it’s	the	first	drug	capable	of	treating	cystic	fibrosis	aetiology	rather	than	
its	symptoms	in	a	specific	subset	of	mutations.		
	
Given	the	impact	Ivacaftor	had	in	the	media	and	that	cystic	fibrosis	 is	not	sufficiently	
known	 in	 our	 society,	 the	 objective	 of	 this	 project	 is	 to	 try	 to	 understand	 the	
underlying	 mechanisms	 of	 cystic	 fibrosis	 disease	 and	 shed	 light	 on	 what	 makes	
Ivacaftor	 a	 remarkable	 advancement	 in	 cystic	 fibrosis	 therapy	 and	 personalised	
medicine.	
	
							1.		Resum	
	
La	Comissió	Europea	defineix	la	medicina	personalitzada	com	a	un	enfocament	mèdic	
que	 utilitza	 els	 coneixements	moleculars	 de	 salut	 i	malaltia	 obtinguts	 a	 travès	 de	 la	
seqüenciació	 del	 genoma	 per	 guiar	 la	 presa	 de	 decisions	 pel	 que	 fa	 a	 la	 predicció,	
prevenció,	diagnòstic	 i	 tractament	de	malalties.	El	seu	objectiu	principal	generalment	
es	 defineix	 com	 "el	 tractament	 adequat	 per	 a	 la	 persona	 adequada	 en	 el	 moment	
adequat”.	
	
Aquest	nou	enfocament	de	 la	medicina	va	atreure	 l'atenció	mundial	al	2012	quan	el	
president	Obama	va	llançar	una	campanya	d’investigació	amb	l’objectiu	d’implementar	
els	 principis	 de	 la	 medicina	 personalitzada	 a	 Amèrica.	 En	 el	 seu	 discurs,	 va	 utilitzar	
l’Ivacaftor	 per	 exemplificar	 el	 potencial	 de	 la	 medicina	 personalitzada.	 El	
desenvolupament	d’Ivacaftor	és	molt	important	ja	que	és	el	primer	fàrmac	que	tracta	
l'etiologia	de	la	fibrosi	quística	enlloc	dels	seus	símptomes	en	un	conjunt	de	mutacions.	
	
Atès	 al	 gran	 ressò	 mediàtic	 que	 l’Ivacaftor	 va	 assolir	 i	 la	 gran	 desconeixença	 de	 la	
societat	 sobre	 la	 fibrosis	 quística,	 l’objectiu	 d’aquest	 treball	 ha	 estat	 conèixer	 la	
fisiopatologia	 d’aquesta	 malaltia	 i	 entendre	 perquè	 aquest	 fàrmac	 suposa	 un	 gran	
avenç	en	medicina	personalitzada	i	en	la	terapèutica	de	la	fibrosis	quística.	
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2. Integration	of	three	knowledge	areas	
	
The	objective	of	this	project	 is	applying	and	 linking	the	different	knowledge	acquired	
throughout	 the	 degree	 with	 different	 pharmaceutical	 knowledge	 areas.	 This	 project	
has	 been	 supervised	 by	 the	 Biochemistry	 and	Molecular	 Biology	 unit,	 which	mainly	
focuses	 on	 the	 study	 of	 the	 structure	 and	 function	 of	 naturally	 occuring	
macromolecules	 in	 living	organisms.	Nevertheless,	 other	 areas	 such	as	 Therapeutical	
Pharmacology	and	Pharmaceutical	Technology	will	also	be	considered.	
	
As	mentioned	above,	the	field	of	Biochemistry	and	Molecular	Biology	is	the	backbone	
of	 this	 project.	 Consequently,	 the	 project	 will	 explore,	 from	 a	 biomolecular	
perspective,	 cystic	 fibrosis	 patophysiology	 and	 diagnosis	 as	 an	 example	 of	 applied	
personalised	medicine	in	modern	healthcare.	
	
In	 the	 secondary	 area,	 therapeutical	 pharmacology,	 the	 project	 will	 study	 the	
therapeutics	of	Ivacaftor,	a	novel	drug	used	to	treat	certain	cystic	fibrosis	variants	with	
specific	mutations	in	the	cystic	fibrosis	transmembrane	regulator	(CFTR)	gene.	
	
Lastly	but	not	 leastly,	 the	birth	of	personalised	medicine	 cannot	be	 fully	understood	
without	 the	 recent	 technological	 advancements	 in	 the	 field	 of	 genomics	 and	
bioinformatics.	 For	 this	 reason,	 I	 will	 keep	 track	 of	 these	 recent	 technological	 leaps	
that	have	helped	shape	nowadays	personalised	medicine	approach.	
	
In	summary,	 the	effort	done	 in	 integrating	the	above	mentioned	areas	of	knowledge	
will	help	make	possible	 the	achievement	of	 the	main	objective	of	 the	project,	which	
was	 	gaining	an	 insight	 into	the	potential	benefits	of	personalised	medicine,	not	only	
from	 a	 genomic	 understanding,	 but	 also	 in	 the	 fields	 of	 drug	 therapy	 and	 the	
pharmaceutical	 technology,	 through	 the	 study	 of	 Ivacaftor	 for	 cystic	 fibrosis,	 a	
revolutionary	drug	where	personalised	medicine	principles	were	recently	applied	and	
remarkable	success	was	achieved.	
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3. Introduction	
	
According	 to	 the	 European	 Commission,	 personalised	 medicine	 refers	 to	 a	 medical	
approach	 that	 uses	 molecular	 insights	 into	 health	 and	 disease	 brought	 on	 by	 the	
sequencing	 of	 the	 genome	 to	 guide	 decision-making	 with	 regard	 to	 the	 prediction,	
prevention,	diagnosis	and	treatment	of	illnesses.	It’s	main	aim	is	generally	perceived	to	
be	 “the	 right	 treatment	 for	 the	 right	 person	 at	 the	 right	 time”(1).	 This	 translates	 in	
offering	 care	 based	 both	 on	 current	 evidence	 and	 patients	 unique	 background	
characteristics	to	enable	proper	predictions	of	their	clinical	outcome.	
	
Everyone	 is	 interested	 in	 the	 idea	 that	 their	medicine	should	be	personalized.	But	 in	
fact,	the	idea	that	we	should	take	care	of	patients	in	a	highly-individualized	way	is	not	
something	new.	Back	 in	ancient	Greece,	Hippocrates	 is	quoted	 for	 saying	“It	 is	more	
important	 to	 know	what	 sort	 of	 person	 has	 a	 disease	 than	 to	 know	what	 sort	 of	 a	
disease	a	person	has”(2).	In	other	words,	it's	more	important	understanding	patient’s	
background	before	trying	to	understand	his	disease.	More	recently,	Sir	William	Osler,	
considered	 by	many	 the	 founder	 of	modern	medicine,	 is	widely	 quoted	 for	 another	
remarkable	 statement	 “The	 good	 physician	 treats	 the	 disease.	 The	 great	 physician	
treats	the	patient	who	has	the	disease.”	Again,	great	physicians	understand	what	it	is	
about	 their	 patient	 that's	 special,	 that's	 individual,	 that's	 unique	 and	 try	 to	 tailor	
therapy	for	them.		
	
In	essence,	physicians	have	known	for	millennia	that	occasional	patients,	for	unknown	
reasons,	seem	to	differ	from	the	average	somehow.	How	susceptible	or	resistant	they	
are	to	certain	diseases,	how	well	they	respond	to	certain	treatments	or	how	badly	they	
tolerate	certain	drugs	has	always	been	a	topic	of	interest	in	medicine.		
	
The	 excitement	 in	 personalised	 medicine	 is	 that	 now	 we	 have	 the	 technological	
capability	to	study	and	understand	what	was	unknown	before.	With	the	new	tools	that	
our	ever-increasing	understanding	of	genetics	and	molecular	biology	provide,	we	have	
now	the	potential	to	explore	and	determine	the	causes	of	this	variability	in	relation	to	
drug	response.	
	
The	 recent	 advancements	 in	 our	 disease	 understanding,	 inevitably	 results	 in	 the	
identification	 of	 differences	 across	 the	 same	 disease.	 In	 consequence,	 stratification	
into	 smaller	 subtypes	 of	 said	 disease	 usually	 takes	 place.	 However,	 classic	 drug	
development	has	always	been	about	the	performance	of	drugs	in	very	large	population	
samples.	This	approach,	 the	so	called	 the	“one	drugs	 fits	all”,	dismisses	 the	 inherent	
individual	variability	among	individuals	while	targeting	a	common	condition	that	hasn’t	
been	properly	 stratified	 yet.	 Consequently,	 it’s	 rare	 for	 classic	 drugs	 to	be	both	 safe	
and	effective	to	everyone,	and	in	most	cases	several	irresponsive	patients	appear.		
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Luckily,	we	are	now	moving	away	from	this	era	of	blockbuster	drugs	designed	to	treat	
huge	amounts	of	patients	with	a	common	complex	disease.	For	this	and	other	reasons,	
modern	 healthcare	 and	 the	 pharmaceutical	 industry	 is	 undergoing	 a	 radical	 shift	
towards	 a	more	 specific,	 tailored	 and	 patient	 driven	 drug	 development.	 In	 this	 new	
model,	 regulatory	 agencies	 no	 longer	 focus	 drug	 evaluation	 solely	 in	 drug’s	 average	
efficacy	 and	 safety	 in	 a	 given	 population.	 Instead,	 they	 also	 search	 for	 resistant	
subgroups	 of	 patients	 whose	 treatment	 failed	 and	 demand	 further	 investigation	 to	
explore	these	phenomena.		
	
However,	traditional	clinical	medicine	approach	for	treating	these	irresponsive	groups	
of	patients	is	following	a	flowchart	of	treatment	options,	whereby	trial	and	error	is	the	
way	 to	 reach	 the	 ‘best’	 treatment	 for	 an	 irresponsive	 patient(3).	 This	methodology,	
frequently	 used	 while	 treating	 common	 multifactorial	 diseases	 such	 as	 diabetes,	
hypertension	 or	 depression,	 often	 leads	 to	 several	 inappropriate	 and	 ineffective	
prescriptions,	 causing	 inadequacies	 and	 several	 adverse	 drug	 events.	 Unfortunately,	
this	keeps	going	on	until	the	most	tolerated,	but	not	necessarily	best,	combination	of	
drugs	to	treat	a	“resistant”	individual	is	prescribed.		
	
The	acknowledgment	of	the	magnitude	of	adverse	drug	events	impact,	which	accounts	
in	the	USA	for	an	annual	sum	of	120.000	deaths	and	its	economic	impact	of	21M$	per	
100.000	 habitants(4),	 can	 give	 us	 a	 good	 idea	 of	 the	 importance	 of	 preventing	 such	
events	both	for	patients	well-being	and	for	healthcare	providers	budget.		
	
There	 are	 several	 confounding	 factors	 that	 can	 determine	whether	 a	 patient	will	 be	
responsive	 to	 a	 drug	 or	 suffer	 an	 adverse	 drug	 event.	 Just	 to	 name	 a	 phew:	 miss-
dosing,	 genetic	 background,	 drug	 interactions	 and	 allergies	 among	 others.	 Although	
this	may	be	 true,	 a	patient’s	 individual	 genetic	predisposition	 for	 inappropriate	drug	
response	remains	the	 least	studied	factor(5).	This	 is	surprising	because	provided	that	
it’s	 been	 well-documented,	 from	 as	 early	 as	 the	 90s,	 that	 in	 some	 cases,	
polymorphisms	 in	 drug	 transporters	 or	 key	 drug	metabolizing	 enzymes	 can	 increase	
toxicity,	cause	adverse	drug	events	or	end	up	with	therapeutic	failure(6).		
	
With	the	promise	of	the	ability	to	properly	estimate	patient’s	likelihood	to	respond	to	
a	 given	 drug	 and	 identifying	 those	 at	 most	 risk	 to	 suffer	 an	 adverse	 drug	 event,	
predicting	 its	 risk	 and	 intervening	 accordingly,	 a	 new	 emerging	 approach	 is	 gaining	
recognition:	personalised	medicine.	
	
Notable	areas	of	study	where	personalised	medicine	can	shed	some	light	and	advance	
clinical	practice	are	the	general	 lack	of	efficacy	of	many	pharmacological	 treatments,	
shown	 in	 figure	1,	 or	 explore	 and	account	 for	 the	diverse	 and	 complex	 variability	of	
drug	rates	of	metabolism	among	patients,	displayed	in	figure	2.				
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One	of	these	new	tools	that	can	help	boost	our	understanding	of	these	differences	in	
patient’s	 response	 is	a	much	deeper	understanding	of	genomics.	 From	1953	Watson	
and	 Crick’s	 outstanding	 discovery	 of	 DNA	 structure(9),	 we	 are	 now	 capable	 of	
sequencing	 a	 whole	 human	 genome	 in	 24	 hours	 for	 1500$(10).	 The	 recent	
advancement	 in	 next-generation	 sequencing	 (NGS)	 methods	 provide	 a	 cheap	 and	
reliable	 large-scale	sequencing	technology.	They	are	used	extensively	for	sequencing,	
disease	mapping,	SNP	tagging,	 to	quantify	expression	 levels	 through	RNA	sequencing	
and	 also	 in	 population	 genetic	 studies	 such	 as	 genome	 wide	 association	 studies	
(GWAS)	that	help	scientists	study	and	determine	genes	role	in	relation	to	disease(11).	
	
As	 demonstrated	 in	 figure	 3,	 these	 technologies	 are	 in	 continuous	 improvement.	 In	
fact,	 the	cost	per	Mb	of	data	has	decreased	tremendously,	 from	nearly	3000$/Mb	in	
the	first	platforms	towards	a	mere	amount	of	0.07$/Mb	in	the	platform	Ilumina	Hi-seq	
2000(12).	 It	 is	 theorized	 that	 this	 rate	of	acceleration	 in	 sequencing	output	 is	 clearly	
just	 beginning.	 Recent	 NGS	 platforms	 just	 introduced	 to	 the	 market	 will	 have	 a	
continuing	and	lasting	impact	on	biomedical	research	for	years	to	come.	As	technology	
advances,	current	 instruments	will	 continue	to	evolve,	at	a	 rate	even	 faster	 than	the	
rate	of	advancement	 in	computer	throughput	pedicted	by	Moore’s	 law	(10).	 In	other	
words,	 the	 time	 it	 takes	 for	DNA	sequencing	output	 to	double	 is	 less	 than	one	year.	
Correspondingly,	NGS	technologies	have	room	for	improvement	for	many	years(13).	
	
But	it's	important	to	understand	that	without	the	implosion	of	modern	bioinformatics,	
among	many	other	disciplines,	we	would	not	be	able	to	gather	and	analyse	those	huge	
DNA	 sequences	 and	 understand	 how	 they	 should	 be	 applied	 to	 individual	 patients.	
Whereas	 in	 the	 past,	 in	 early	 Sanger’s	 sequencing	 times,	 when	 sequencing	 was	
extremely	 slow,	 sequence	 output	 was	 the	 true	 rate	 limiting	 in	 advancing	 biological	
understanding,	 nowadays,	 with	 the	 current	 platforms,	 it’s	 data	 interpretation,	
bioinformatics,	that	limits	the	rate	of	advancement	in	biological	understanding(13).		
Figure	1:	Response	rates	of	patients	to	a	major	drug	for	
a	selected	group	of	therapeutic	areas(7).	
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Figure	2:	Distribution	of	the	maximum	tolerated	
carbamazepine	dose	in	a	study	with	241	people(8). 
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To	clarify,	 the	 revolution	 in	personalised	medicine	 is	mainly	 taking	advantage	of	 two	
developments,	 one	 in	 the	 science	 of	 genomics,	 with	 advancements	 in	 genetic	
technologies	 and	 techniques	 such	 as	 genotyping	 or	 microarrays,	 and	 the	 other,	 in	
bioinformatics,	with	advancements	in	algorithms,	huge	data	processing	and	even	deep	
machine	 learning.	 Both	 have	 been	 pillars	 and	 sources	 of	 information	 to	 effectively	
apply	 personalised	medicine.	 An	 important	 distinction	 to	 draw	 is	 that	 by	 huge	 data	
sets	we	are	not	 just	 limited	 to	molecular	DNA	sequencing	data,	but	also	many	other	
types	of	molecular	data,	ranging	from	epigenetics,	mRNA	expression,	metabolomics	or	
proteomics.	Another	equally	 important	 type	of	data	 is	 none	molecular	data,	 such	as	
the	information	contained	in	patient	record	files	or	from	patient’s	blood	analysis.		
	
All	 these	 sorts	 of	 data	 are	 what’s	 shaping	 modern	 bioinformatics	 and	 what	 makes	
feasible	the	current	personalised	medicine	approach.	In	the	future,	we	will	learn	more	
about	disease	 susceptibility	 and	drug	 response	by	 looking	 at	molecular	 data	 such	 as	
DNA	patterns	or	mRNA	expression	levels	combined	with	none	molecular	data	such	as	
patterns	in	electronic	medical	records	or	blood	samples	and	understand	what	it	is	that	
makes	an	 individual	or	 a	disease	 special.	 In	 this	 setting,	bioinformatics	purpose	 is	 to	
investigate	 those	 tremendously	 large	 data	 sets,	 analyse	 their	 interrelationships	 and	
extract	clinically	valuable	information	for	both	scientists	and	physicians.	
	
Therefore,	 personalised	 medicine	 seeks	 to	 move	 away	 from	 the	 classic	 heavily	
symptom-based	diagnostics	towards	a	model	where	molecular	characterisation	is	the	
main	indicator	of	disease	diagnosis	and	prognosis.	This	approach,	alternatively	known	
as	biomarkers	based	medicine,	 is	what	ultimately	will	 guide	and	 improve	physician’s	
decision	making	and	enable	a	true	individualisation	of	patients.		
Figure	3:	Changes	in	NGS	instrument	capability	over	the	past	decade	and	the	timing	of	major	sequencing	projects.	
At	 the	 top,	 increasing	 scale	 of	 data	 output	 per	 run	 plotted	 on	 a	 logarithmic	 scale.	 In	 the	 middle,	 a	 timeline	
representing	major	milestones	in	massively	parallel	sequencing	platforms.	Bottom,	the	timing	of	important	projects	
and	milestones	in	the	field	of	genomics	(13). 
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Although	personalised	medicine	is	often	
considered	 to	 be	 mostly	 based	 on	
genomics	 and	 bioinformatics,	 it’s	 the	
result	 of	 a	 far	 more	 complex	 network	
from	 the	 combination	 of	 science,	
technology,	 engineering	 and	 medicine	
fields	(STEM)	as	shown	in	figure	4.				
	
In	 addition	 to	 the	 genes,	 several	 other	
factors	that	vary	among	individuals	can	
influence	 drug	 response	 or	 disease	
course,	and	 thus,	must	also	be	 studied	
and	 properly	 addressed.	 For	 instance,	
the	 characterization	 of	 the	 intestine	 flora,	 the	 microbiome,	 which	 has	 been	
demonstrated	 to	 interfere	 in	 drug	metabolism	 and	 to	 play	 a	 central	 role	 in	 human	
health,	 has	 the	potential	 to	help	determine	 current	patient	 immune	 status	 and	help	
predict	 patients	 susceptibility	 to	 certain	 diseases	 such	 as	 Crohn’s	 disease,	
Inflammatory	bowel	disease	or	obesity(15).		
	
Another	example	of	a	factor	to	consider	in	personalised	medicine	is	circadian	rhythms,	
which	 through	various	endogenous	physiological	 and	metabolic	processes	determine	
the	daily	fluctuations	of	parameters	such	as	the	heart	rate,	renal	activity	or	endocrine	
secretion.	These	fluctuations,	which	broadly	differ	in	relation	to	gender,	age	and	health	
state,	 can	 directly	 affect	 drugs	 half-life.	 Recently,	 chronoparmacokineticists	
demonstrated	 that	56	out	of	 the	100	best	 selling	drugs	 in	 the	US	 target	products	of	
genes	 in	 clinically	 relevant	 organs	 whose	 expression	 cycles	 significantly	 oscillate	
according	 to	 circadian	 rhythms,	 and	 thus,	 their	 efficacy	 fluctuates	 depending	 on	 the	
time	of	administration(16).	Therefore,	we	must	transition	from	the	general	three	daily	
standard	recommendation	to	virtually	everyone	and	instead,	if	necessary,	establish	the	
optimal	hours	of	administration	according	to	each	patient’s	unique	characteristics.		
	
But	 besides	 the	 difficulties	 of	 the	 challenge	 of	 individualising	 healthcare,	 the	
implementation	of	this	new	approach	faces	many	other	problems	of	different	nature.	
What	many	healthcare	professionals	encounter	 in	 their	daily	practice	 is	 that	patients	
level	of	excitement	around	 the	concepts	of	personalised	medicine	vary	broadly.	 This	
happens	 for	many	 reasons	unrelated	 to	 their	 biological	 health,	 but	 rather	with	 their	
environment,	the	way	they	were	brought	up,	their	educational	level	and	their	religious	
beliefs.	 Popular	 examples	 include	 the	 Amish	 denial	 of	 modern	 medicine,	 Church	 of	
Scientology	stance	on	any	sort	of	psychiatry	or	Jehovah	witnesses	refusal	of	any	blood	
transfusion.	By	and	large,	the	way	patients	were	brought	up	can	make	a	big	difference	
in	their	attitude	towards	personalised	medicine.		
Figure	 4:	 A	 schematic	 diagram	 intending	 to	 display	 the	
complex	relationships	established	between	different	STEM	
fields	that	currently	shape	personalised	medicine(14).	
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Given	 these	 points,	 a	 more	 updated	 and	 mandatory	 health	 education	 should	 be	
encouraged(3).	We	should	promote	early	educational	campaigns	designed	to	facilitate	
the	 communication,	 in	 layman	 terms,	 of	 basic	 key	 health	 concepts	 of	 personalised	
medicine	so	they	are	aware	of	this	new	paradigm	shift.	Understanding	terms	such	as	
what	a	mutation	is	or	what	is	the	purpose	of	sequencing	the	genome,	should	become	
common	knowledge	to	virtually	everyone.		
	
Equally	important	is	promoting	its	implementation	in	healthcare	services.	Despite	the	
efforts	done	in	this	direction,	a	survey	conducted	to	2000	canadian	physicians	in	2015	
outlined	that	although	the	majority	of	practitioners	 recognised	the	positive	potential	
of	 genetic	 testing	 in	 disease	 management	 (71%);	 problems	 such	 as	 lack	 of	 clinical	
evidence	 (53%),	 the	 prohibitive	 cost	 of	 	 tests	 (48%)	 or	 lack	 of	 adequate	 guidelines	
(60%)	are	still	fundamental	barriers	for	adoption	of	use(17).		
	
Correspondingly,	to	allow	widespread	personalised	
medicine	implementation,	regulatory	bodies	across	
the	 world	 are	 developing	 a	 range	 of	 different	
initiatives.	 Notable	 examples	 in	 Europe	 include	
EMA’s	development	of	Supplementary	Information	
S1,	 a	 regulatory	 framework	 aiming	 to	 harmonize,	
among	other	things,	current	biospecimen	sampling	
and	 guarantee	 proper	 clinical	 validity	 of	 new	
biomarkers	or	the	programme	Horizon	2020,	a	70€	
billion	investment	by	the	European	Commission,	to	
fight	current	lack	of	funding	in	collaborative	health	
research	and	boost	our	disease	understanding	are	
examples	of	such	initiatives(5).		
	
On	the	other	side	of	the	Atlantic,	FDA’s	2011	report	
titled	 “Paving	 the	 way	 for	 personalised	medicine”	
outlined	 the	 steps	 the	 agency	 would	 take	 to	
integrate	 genetic	 and	 biomarker	 information,	 to	
develop	 a	 better	 regulatory	 science	 and	 to	 help	
advance	drug	development	(18).		
	
Moreover,	 back	 in	 2014,	 Obama’s	 administration	
launched	 the	 Precision	Medicine	 Initiative,	 shown	
in	 figure	 5,	 to	 accelerate	 biomedical	 research	 and	
provide	clinicians	with	new	tools	to	select	therapies	
that	 work	 best	 in	 individual	 patients	 with	 specific	
diseases(19).		
Figure	 5:	 The	 original	 infographic	 of	
Obama’s	Precision	Medicine	Initiative.	
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Semantically,	 both	 personalised	 medicine	 and	 precision	 medicine	 are	 often	 used	
interchangeably.	However,	 there	 is	 a	 concern	 that	 the	word	 "personalized"	 could	be	
misinterpreted	to	imply	that	treatments	and	preventions	are	being	developed	uniquely	
and	solely	for	each	individual	patient,	although	this	could	be	true	to	some	extent,	the	
precision	 medicine	 term	 focuses	 mainly	 on	 identifying	 which	 approaches	 will	 be	
effective	 for	 patients	 based	 on	 genetic,	 environmental	 and	 lifestyle	 factors(20).	 This	
distinction,	 coupled	 with	 the	 fact	 that	 precision	 medicine	 current	 definition	 among	
experts	is	generally	understood	as	an	approach	to	understand	disease	in	a	deeper	level	
in	 order	 to	 develop	 a	 more	 targeted	 therapy,	 makes	 the	 precision	 medicine	 term	
preferable.	
	
During	Obama’s	presentation	speech	of	the	Precision	Medicine	Initiative,	he	utilised	as	
an	example	of	 the	potential	benefits	of	 applying	precision	medicine	 towards	disease	
advancement	 the	 case	 of	 cystic	 fibrosis	 and	 the	 recent	 development	 of	 Ivacaftor,	 a	
novel	drug	used	for	a	specific	subset	of	cystic	fibrosis	variants.		
	
Cystic	fibrosis	(CF)	is	a	rare,	life	threatening,	autosomal-recessive	genetic	disorder	that	
affects	many	 systems,	 including	 the	 gastrointestinal,	 reproductive	 and	 specially,	 the	
respiratory	 system.	 It	 is	 the	most	 common	 fatal	 genetic	 disorder,	most	 prevalent	 in	
caucasian	descent	population,	as	 shown	 in	 figure	6,	and	has	a	highly	variable	clinical	
presentation	 and	 course	 depending	 on	 specific	mutations,	 several	 genetic	modifiers	
and	environmental	factors.	Until	recently,	no	treatments	were	available	that	targeted	
the	 underlying	 cause	 of	 cystic	 fibrosis	 and	 consequently,	 all	 available	 treatment,	
consisting	 of	 preventive	 antibiotics,	 bronchodilators,	 mucus	 thinners,	 steroids	 and	
enzymes,	 was	 merely	 symptomatic,	 focused	 on	 treating	 its	 manifestations	 and	
secondary	diseases.			
	
	
	
	
	
	
	
	
	
	
	
	
Luckily,	 this	all	 changed	with	 the	market	 launch	 in	2012	of	 Ivacaftor,	a	novel	 first-in-
class	 drug	 that	 specifically	 targets	 cystic	 fibrosis	 aetiology	 rather	 than	 symptoms.	 It	
works	 by	 potentiating	 the	 function	 of	 the	 CFTR	 channel	 (the	 dysfunction	 of	 which	
causes	cystic	fibrosis)	in	a	subgroup	of	patients	carrying	specific	mutations.		
Figure	6:	Estimated	prevalence	of	cystic	fibrosis	per	100.000	habitants(21).	
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The	 drug	 was	 discovered	 after	 decades	 of	 intense	 research	 after	 application	 of	
genomics	 in	 different	 stages	 of	 the	 drug	 development.	 After	 several	 collaborative	
projects	 between	 patients,	 scientists	 and	 the	 drug	 manufacturer,	 researchers	
investigating	CF	finally	understood,	at	a	molecular	level,	the	reasons	why	CFTR	fails	to	
function.	Based	on	this	knowledge,	 the	drug	manufacturer	designed	successful	cystic	
fibrosis	 in	 vitro	 models	 and	 via	 high-throughput	 screening	 identified	 a	 molecule	
capable	 of	 reverting	 this	 malfunction.	 Then,	 through	 iterative	 medicinal	 chemistry	
techniques,	the	manufacturer	developed	a	drug	capable	of	improving	CFTR	activity	in	a	
concrete	 subset	 of	 specific	 mutations(22).	 Shortly	 after,	 the	 developer	 of	 Ivacaftor	
designed	a	genetic	test	to	determine	patient’s	eligibility	for	treatment.	Without	delay,	
the	 drug	 was	 studied	 in	 clinical	 trials	 with	 patients	 possessing	 these	mutations.	 It’s	
success	lead	to	the	EMA’s	and	FDA’s	approval	of	the	first	CFTR	potentiator.	Both	drug	
applications	were	granted	the	orphan	drug	designation	and	the	priority	review	status.	
In	FDA’s	case,	it	set	an	historical	all	time	low	record	time	of	approval	of	3	months(18).	
	
Another	 remarkable	 aspect	 in	 the	 drug	 development	 of	 Ivacaftor	 that	 sets	 it	 as	 the	
perfect	 example	 for	 future	 drug	 development	 is	 the	 path	 that	 ultimately	 led	 to	 the	
discovery	 of	 Ivacaftor	was	 remarkably	 patient	 driven.	 The	 drug	 itself	 came	 out	 of	 a	
collaboration	 between	 the	 drug’s	 manufacturer	 and	 the	 Cystic	 Fibrosis	 Foundation	
(CFF)(23).	 CFF	 has	 fought	 cystic	 fibrosis	 for	many	 years,	 organizing	 and	 coordinating	
the	patient	community	and	helping	fund	the	research	that	led	to	the	discovery	of	CFTR	
sequence	back	in	1989(24).	CFF	has	also	helped	in	the	establishment	of	a	large	public	
CF	patient	 registry	mutation	databank	 (Cystic	 Fibrosis	Mutation	Database)	 accessible	
for	free	for	researchers	all	over	the	world(25)	and	has	helped	establish	the	clinical	trial	
network	for	investigating	and	determining	the	genetics	of	the	disease	while	recruiting	
participants	 for	 testing	candidate	drugs	aswell(18).	The	 foundation	 itself	helped	 fund	
Ivacaftor	discovery	and	development	with	a	total	amount	of	75M$(26).		
	
Overall,	 the	 drug	 itself	 was	 such	 a	 breakthrough	 in	 both	 drug	 development	 and	 in	
cystic	fibrosis	clinical	management,	that	it	was	described	as	a	wonder	drug	among	the	
medical	 community	 and	 labelled	 as	 “The	 most	 important	 drug	 of	 2012”	 by	 Forbes	
magazine(27).		
	
All	 things	 considered,	 the	 special	 nature	 of	 cystic	 fibrosis	 disease,	 the	 amount	 of	
research	conducted	over	several	decades	and	the	singular	characteristics	of	 Ivacaftor	
development	make	 it	 a	 great	example	of	 the	 revolutionary	potential	 of	personalised	
medicine.	 With	 all	 this	 in	 mind,	 I	 decided	 to	 investigate	 further	 cystic	 fibrosis	 and	
Ivacaftor	throughout	the	course	of	this	project.	
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4. Personalised	medicine	of	cystic	fibrosis	
	
Cystic	fibrosis	(CF)	is	a	classic	Mendelian	disorder	caused	by	mutations	in	the	gene	that	
encodes	 an	 epithelial	 ion	 channel	 known	 as	 the	 cystic	 fibrosis	 transmembrane	
conductance	 regulator	 (CFTR).	 The	 disease	 is	 transmitted	 in	 an	 autosomal	 recessive	
manner	 and	 is	 the	 most	 common	 lethal	 inherited	 genetic	 disorder,	 affecting	 over	
70.000	individuals	worldwide(19).	It	is	most	prevalent	in	caucasians	with	an	estimated	
incidence	of	1:2500	in	this	particular	population	as	shown	in	figure	6.		
	
CF	pathophysiology	is	caused	by	CFTR	protein	malfunction,	which	is	expressed	across	
many	cell	types	and	is	involved	in	the	production	of	sweat,	digestive	fluids	and	mucus	
in	 several	 organs.	 Its	 impairment	 affects	 airways,	 sinuses,	 the	 intestinal	 tract,	 the	
genitourinary	 system,	 the	 pancreas	 and	 the	 biliary	 system.	 This	 leads	 to	 a	wide	 and	
variable	 array	 of	 clinical	 manifestations	 and	 complications,	 shown	 in	 figure	 7,	 the	
severity	 of	 which	 depend	 not	 only	 on	 the	 specific	 CFTR	 genotype	 but	 also	 on	
environmental	factors	and	genetic	modifiers,	regions	of	the	genome	outside	the	CFTR	
gene	that	influence	cystic	fibrosis	course.	
	
Although	 it	 has	been	 theorized	 that	 cystic	 fibrosis	has	been	around	 from	as	early	 as	
3000BC,	 it	was	 first	described	on	medical	 literature	by	Dr.	Hansine	 in	1936(28),	who	
first	linked	cystic	fibrosis	pancreatic	problems	with	abnormal	pulmonary	and	intestinal	
malfunction.	 She	 was	 the	 first	 physician	 to	 use	 pancreatic	 enzyme	 replacement	
therapy	to	treat	affected	children	and	established	the	first	cystic	fibrosis	diagnosis	test.	
When	CF	was	 first	described,	patient’s	 life	was	painful	and	short	as	 seen	 in	 figure	8.	
However,	 as	 pancreatic	 supplementation	 became	 widely	 available	 and	 preventive	
antibiotics	began	to	be	used,	coupled	with	an	improved	patient	care	and	nutrition,	the	
life	expectancy	and	quality	of	life	for	cystic	fibrosis	patients	increased	dramatically.		
Figure	 8:	 Growth	 in	 CF	 patient’s	 life	
expectancy	 in	 the	 last	century.	Reaching	
a	 total	 of	 32	 life	 years	 in	 2000,	 it’s	
expected	 to	 surpass	 the	 50	 life	 years	
mark	in	new	borns	after	2000(29).	(Data	
source:	Cystic	Fibrosis	Foundation(26)).	
Figure	7:	The	most	common	cystic	fibrosis	traits	and	their	relative	relationship	with	the	CFTR	genotype.	As	displayed	
in	the	image,	CFTR	genotype	alone	doesn’t	account	for	all	CF	phenotypes.	However,	for	some	traits,	such	as	pancreas	
exocrine	insufficiency,	CFTR	genotype	 is	 the	primary	determinant.	On	the	other	hand,	 for	other	traits	such	as	cystic	
fibrosis-related	diabetes,	the	main	determinant	of	the	phenotype	are	the	genetic	modifiers(30).	
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One	 of	 the	most	 challenging	 problem	 in	 the	management	 of	 cystic	 fibrosis	 and	 the	
major	determinant	of	patient’s	quality	of	 life	and	 life	 span	 is	pulmonary	disease(31).	
Due	 to	CFTR	malfunction,	as	 shown	 in	 figure	9,	 the	 lack	of	 transport	of	 chloride	and	
excessive	 sodium	 reabsorption	 cause	 absorption	 of	 water	 via	 osmosis	 across	 all	
respiratory	tract	leading	to	a	dehydrated	airway	surface	fluid	and	impairing	mucociliary	
clearance.	Ultimately,	this	excessive	viscid	mucus	drastically	increases	the	incidence	of	
infections	 by	 the	 entrapment	 of	 bacteria	 in	 airway	 secretions	 and	 causes	 local	
inflammation	 in	 response(32).	 As	 a	 result,	 chronic	 lung	 infection	 incidence	 in	 cystic	
fibrosis	patients	is	high	and	steadily	increases	with	age	due	to	different	mechanisms.		
	
Firstly,	 bacterial	 adaptation	 to	 the	 airway	 environment	 ensues	 with	 a	 shift	 from	
planktonic	to	a	biofilm	mode	of	growth	by	pressure	selection	of	mutant	bacteria	with	
abundant	exopolysaccharide	production	capable	of	eluding	physiological	phagocytosis.	
Secondly,	 the	 nature	 of	 the	 infection	 causal	 agents	 varies	 a	 lot	 and	 shifts	 with	 age	
(figure	10).	Finally,	and	more	importantly,	is	the	appearance	of	multiresistant	bacteria	
promoted	by	the	persistent	prophylactic	antibiotic	use.	Therefore,	failure	in	antibiotic	
therapy	is	common,	explaining	the	difficulty	of	CF	pulmonary	disease	management.	
	
As	 bacteria	 chronification	 advances,	 the	 tissue	 promotes	 a	 much	 more	 intense	
inflammation	 causing	 severe	obstruction	of	 airway	 flow,	destruction	of	 airway	walls,	
fibrosis	and	characteristic	cysts(33),	clearly	seen	in	figure	11,	hence	the	disease	name.	
The	sum	of	all	these	physical	changes	in	the	respiratory	tissue	lead	to	a	life-threatening	
decreased	lung	function	to	the	point	that	some	CF	patients	must	undergo	pulmonary	
transplant	to	carry	on	living	if	they	don’t	die	first	from	this	condition(29).			
Figure	10:	Evolution	of	the	causal	agents	and	incidence	
of	 infection	 in	 relation	 to	age.	 The	 colonization	occurs	
typically	in	early	ages	with	S.	aureus	and	shifts	towards	
P.	aeruginosa	in	adulthood(26).	(CFF,	2010).	
Figure	 9:	 Cartoon	 displaying	 the	 mechanism	
underlying	 the	 surge	 in	 infections	 in	 CF	patients.	 The	
deficient	 CFTR	 ion	 transport	 cannot	properly	 hydrate	
airway	mucus	by		causing	bacteria	entrapment(34).	
Figure	 11:	 Comparison	 of	 two	 X-ray	 chest	
radiographs.	On	the	left,	a	healthy	pair	of	adult	lungs.	
On	 the	 right,	 the	 lungs	 of	 an	 adult	 with	 advanced	
cystic	 fibrosis.	 Quoting	 the	 original	 pneumologist	
description:	 In	 the	CF	 lungs	we	 can	observe	a	 severe	
bronchiectasis	with	numerous	mucoid	impactations,	a	
retraction	of	both	hilar	 regions	due	 to	tissue	 scarring	
and	 a	 marked	 hyperexpansion.	 (Source	 of	 images:	
Carol	Black,	MD,	UpToDate,	2017).	
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Interestingly,	 this	exacerbated	 local	 inflammation	does	not	only	occur	 in	 response	to	
the	presence	of	microbial	signalling.	CFTR	mutations	alone	have	been	associated	with	
constitutive	 pro-inflammatory	 signalling,	 increased	 oxidative	 stress	 and	 exaggerated	
response	towards	bacteria.	Moreover,	CFTR	is	also	expressed	in	lymphocytes	and	some	
mutations	have	been	shown	to	alter	host-pathogen	interactions,	 interfering	 in	 innate	
immune	lung	cell	function	and	causing	a	pulmonary	mucosal	immunodeficiency(32).		
	
In	the	pancreas,	the	build-up	of	mucus	prevents	the	release	of	digestive	enzymes	that	
help	break	down	food	and	absorb	nutrients.	Consequently,	people	with	CF	often	have	
a	marked	malnutrition	and	poor	growth.	To	tackle	this	problem	oral	pancreatic	enzyme	
supplementation	 is	 strongly	 recommended	 as	 85%	 of	 CF	 patients	 have	 pancreatic	
insufficiency(21).	Those	supplements	are	directly	obtained	 from	pig	pancreatic	 tissue	
lysis	 and	 posterior	 protein	 purification.	 They	 consist	 of	 a	 combined	 form	 of	 lipase,	
protease	and	pancreatic	amylase	enzymes	mixture	and	are	dose-adjusted	according	to	
patient	exocrine	degree	of	 insufficiency.	Furthermore,	thick	mucus	can	also	block	the	
bile	duct	in	the	liver	and,	in	some	cases,	cause	liver	diseases.		
	
Lastly,	male	 infertility	rates	 in	CF	are	extremely	high,	97%(35).	Male	new	borns	often	
have	a	congenital	bilateral	absence	of	vas	deferens,	the	tube	that	carries	sperm	from	
the	 testiscles	 to	 the	 penis,	 resulting	 in	 an	 obstructive	 azoospermia	 that	 cannot	 be	
surgically	 corrected.	 However,	 modern	 fertility	 techniques	 that	 combine	 testicular	
sperm	extraction	and	intracytoplasmic	sperm	injections	can	help	assist	some	cases.			
	
However,	 contrary	 to	 the	 popular	 belief,	 cystic	 fibrosis	 does	 not	 cause	 mental	
retardation	or	learning	problems.	Neither	affects	mobility	or	mean	a	person	will	have	
to	use	a	wheelchair.	In	fact,	children	born	today	with	CF	are	expected	to	have	normal	
schooling	and	reach	average	academic	achievement(36).	
	
Cystic	fibrosis	diagnosis	usually	occurs	in	early	ages	(figure	12)	but	used	to	be	troubling	
way	 back	when	 genotyping	 of	 CFTR	 or	 new	 born	 screening	 (NBS)	weren’t	 a	 routine	
medical	procedure.	Physicians	had	to	rely	on	diagnosis	based	on	new	born	signs	and	
symptom	 such	 as	 delayed	 growth,	 failure	 to	 obtain	 normal	 weight,	 lack	 of	 bowel	
movements	or	salty-tasting	skin.	As	we	gained	more	knowledge	of	CF	and	sequencing	
technology	advanced,	besides	a	much	 thorough	and	broader	study	of	 symptoms,	we	
rely	now	on	immunoreactive	trypsinogen	test	(NBS),	genetic	testing	and	sweat	chloride	
test	 to	 diagnose	 CF.	 Other	 tests	 include	 secretin	 stimulation	 tests,	 X-rays	 of	 chest,	
upper	GI	and	small	bowel,	lung	function	test	or	the	analysis	of	meconium	fat.		
Figure	 12:	 Snapshot	 of	 2007	 displaying	 the	 age	 of	
diagnosis	 for	 CF	 in	 the	 USA.	 As	 we	 can	 see	 in	 the	
graph,	 66%	 of	 patients	 with	 CF	 were	 diagnosed	 in	
their	 first	 life	 year	 and	 only	 2%	 of	 CF	 patients	 are	
diagnosed	with	CF	before	being	born.	In	2013,	60%	of	
new	diagnoses	of	 CF	were	detected	by	NBS.	 (Source:	
Cystic	fibrosis	foundation(26)).	
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The	complete	NBS	for	CF	is	increasingly	being	implemented	across	the	globe	because	
early	 detection	permits	 sooner	 access	 to	 specialized	medical	 care	which	 significantly	
improves	patient’s	outcomes.	Nowadays,	NBS	in	Europe	and	the	USA	is	universal(37),	
with	variations	of	the	exact	screening	panel	between	countries.		
	
Although	 the	 sweat	chloride	 test	 remains	 the	gold	 standard	 for	CF	diagnosis,	 it	does	
not	always	give	a	clear	and	definitive	diagnosis	as	shown	in	figure	13.	Instead,	modern	
guidelines	for	diagnosing	CF	recommend	that	an	individual	should	meet	all	four	items	
of	 the	 following	criteria(37):	 In	 the	 first	place,	patient	has	 to	present	evident	 clinical	
manifestations	 of	 CF;	 secondly,	 a	 demonstrated	 CFTR	 dysfunction	 as	 measured	 by	
sweat	 chloride	 test;	 thirdly,	 positive	 testing	 in	 NBS;	 finally,	 found	 carrier	 of	 a	 CFTR	
pathogenic	variant	in	a	gene	analysis.	While	CF	diagnosis	is	evident	when	subjects	are	
carriers	 of	 CF-causing	 variants	 on	 both	 alleles,	 further	 extended	 CFTR	 testing	 is	
recommended	 if	 sweat	 chloride	 test	 results	 are	 inconclusive	 and	 only	 a	 single	 CF	
mutated	allele	with	a	suspected	but	not	confirmed	to	cause	CF	mutation	is	found(38).		
(39)	
In	an	attempt	to	prevent	CF,	genetic	testing	on	parents	with	CF	family	history	prior	to	
pregnancy	is	often	recommended(37)	because	development	of	CF	in	the	fetus	requires	
each	 parent	 to	 pass	 on	 a	 mutated	 copy	 of	 the	 CFTR	 gene.	 Since	 CF	 genotyping	 is	
expensive,	testing	is	often	performed	initially	on	one	parent.	 If	results	 indicate	that	a	
parent	is	a	CFTR	gene	mutation	carrier,	the	other	parent	is	tested	and	the	risk	of	their	
child	 to	 develop	 CF	 is	 calculated	 to	 guide	 parenthood	 decision	making.	 However,	 in	
2016,	only	the	most	common	mutations,	such	as	ΔF508,	are	tested(29,40).		
	
Recently,	 advancements	 in	 genomics,	 especially	 in	 genome	wide	 association	 studies	
(GWAS),	 have	made	possible	 the	discovery	 that	CFTR	genotype	alone	accounts	 for	 a	
modest	 portion	 of	 patient’s	 cystic	 fibrosis	 phenotype	 as	 shown	 in	 figure	 5.	 These	
numerous	 none-CFTR	 genetic	 modifiers,	 regions	 of	 the	 genome	 with	 demonstrated	
linkage	with	 the	 likelihood	 to	 suffer	 severe	 cystic	 fibrosis	 secondary	 diseases,	 play	 a	
role	 in	 the	development	of	 several	 clinical	 features	 such	as	obstructive	 lung	disease,	
intestinal	obstruction,	diabetes	or	susceptibly	versus	P.	aeruginosa		infection(41,30).		
	
	
Figure	 13:	 Extracted	 from	 the	 2017	
consensus	 guideline	 diagnosis	 scheme	 for	
cystic	 fibrosis(38).	 CFTR	 variants	 genetic	
analysis	positive	results	are	classified	 in	 CF-
causing	 (those	 demonstrated	 to	 cause	 CF),	
mutations	 of	 varying	 clinical	 consequences	
(MVCC;	 mutations	 with	 suspected	 but	 not	
confirmed	 causation)	 and	 undefined	
mutation	 for	 those	 with	 unknown	
effects(39).		
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This	 raises	 an	 obvious	 question,	 if	 modern	 technology	 can	 make	 feasible	 the	
determination	of	cystic	fibrosis	patient’s	predisposition	to	suffer	certain	complications	
or	secondary	diseases,	 in	a	certain	degree,	such	as	cystic	fibrosis-related	diabetes,	by	
determining	 their	 full	 genotype	 and	 intervening	 accordingly,	 shouldn’t	 healthcare	
services	recommend	whole	genome	sequencing	(WGS)	for	cystic	fibrosis	patients?	As	
of	today,	5	genome	wide	association	studies	(GWAS)	have	been	published	in	the	GWAS	
Catalogue	Registry	that	helped	establish	20	genes/locus	in	the	genome	now	classified	
as	 genetic	modifiers	 for	 cystic	 fibrosis	 disease(41).	 These	 findings	 provide	 additional	
genetic	targets	and	might	enable	individualized	treatment	of	CF.	With	the	rate	of	on-
going	research,	this	number	will	only	increase	in	the	future.	Should	patients	wait?		
	
We	have	seen	that	sequencing	the	whole	genome	costs	today	1000$	and	this	price	is	
projected	to	halt	in	a	near	future.	Under	this	premise,	the	potential	clinical	benefits	of	
WGS	are	obvious.	CF	patients	are	already	more	prone	to	develop	severe,	and	possibly	
life-threatening,	 diseases	 and	 these	 tools	 can	 effectively	 help	 physicians	 tailor	
treatment,	 offering	 personalised	 preventive	 action	 and	 help	 guide	 decision	 making	
regarding	patients	follow	up.	
	
From	 an	 economic	 standpoint,	 the	mean	 annual	 cost	 of	 CF	 treatment	 per	 patient	 is	
15500$(42),	taking	into	account	the	basic	healthcare	principle	“it’s	always	cheaper	to	
prevent	 rather	 than	 threat	 disease”,	 there	 is	 little	 doubt	 that	 implementing	 this	
approach,	 in	a	personalised	medicine	 fashion,	would	certainly	be	cost-effective.	As	a	
mode	of	example,	if	a	certain	patient	has	its	genome	sequenced	and	its	susceptibility	
to	 suffer	 P.	 aeruginosa	 determined,	 physicians	 could	 prescribe	 a	 more	 adequate	
antibiotic	 scheme	 and	 design	 a	 more	 tailored	 follow	 up.	 Conversely,	 if	 a	 patient’s	
degree	 of	 predisposition	 to	 suffer	 cystic	 fibrosis-related	 diabetes	 is	 previously	
determined,	 perhaps	 an	 early	 introduction	 of	 preventive	 hygienic-diet	 actions	 could	
stop	 the	 disease	 development.	 In	 all	 these	 hypothetical	 scenarios,	 patients	 could	
benefit	greatly	from	whole	genome	sequencing.	
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4.1		Ivacaftor	
	
Ivacaftor	is	a	cystic	fibrosis	transmembrane	conductance	potentiator	(CFTR)	indicated	
for	 the	 treatment	 of	 CF	 in	 patients	 2	 years	 of	 age	 and	 older	who	 have	 at	 least	 one	
allele	with	the	following	mutations	in	the	CFTR	gene:	G551D,	G1244E,	G1349D,	G178R,	
G551S,	S1251N,	S1255P,	S549N,	S549R	or	R117H(43–57).	Ion	channel	modulators	aim	
to	 correct	 the	 underlying	 cellular	 defect	 (chloride	 ion	 transport)	 responsible	 for	 CF	
instead	 of	 the	 severity	 of	 symptoms.	 Despite	 the	 classic	 agonist/antagonist	
denomination	often	used	for	receptor	modulators,	Ivacaftor	was	catalogued	as	a	CFTR	
potentiator	 because	 it	 doesn’t	 open	 the	 channel	 on	 it’s	 own,	 instead,	 it	 works	 by	
increasing	the	likelihood	of	CFTR	channel	opening(46).	
	
The	 exact	mechanism	of	 action	 of	 Ivacaftor	 has	 not	 been	 fully	 elucidated.	However,	
recent	research	suggests	that	it	interacts	with	CFTR	in	an	ATP	independent	manner.	In	
addition	 of	 channel	 gating	 promotion	 in	 both	 G551D-CFTR	 and	 wild	 type-CFTR	
channels,	 Ivacaftor	 demonstrated	 to	 also	 regulate	 other	 CFTR	 downstream	 airway	
functions,	such	as	airway	surface	liquid	depth	and	ciliary	activity(22).	
	
In	preclinical	studies	assessing	 Ivacaftor’s	efficacy,	the	change	 in	G551D-CFTR	activity		
was	 first	 studied	 in	 Fischer	 rat	 thyroid	 cells,	 where	 it	 was	 shown	 to	 increase	 both	
chlorine	 transport	 and	open	probability.	 To	 escalate	 experimenting	 towards	 humans	
further,	 a	model	 with	 greater	 similarity	 with	 CF	 lung	 pathogenesis	 was	 used,	 which	
consisted	 in	 an	 in	 vitro	 model	 of	 human	 bronchial	 epithelial	 cells	 directly	 obtained	
from	CF	patients.	In	this	setting,	ivacaftor	treatment	displayed	increased	G551D-CFTR	
activty	with	sufficient	efficacy	to	restore	salt	and	fluid	balance(46).		
	
Ivacaftor’s	selectivity	for	CFTR	was	excellent	on	an	activity	screening	against	a	panel	of	
enzymes	 and	 receptors,	 which	 included	 11	 other	 ion	 channels.	 Moreover,	 in	 safety	
pharmacology	studies,	no	adverse	effects	were	observed	in	in	vivo	dog	cardiovascular	
safety	 evaluation,	 neither	 in	 neurological	 and	 respiratory	 functions.	 However,	
gastrointestinal	 studies	 indicated	 a	 remarked	 decrease	 in	motility	 up	 to	 49%	 and	 in	
hERG	 assay	 in	 HEK239	 cells	 Ivacaftor	 	 displayed	 a	 35%	 inhibition	 in	 maximal	
concentrations(47).		
	
In	 pharmacokinetic	 studies,	 Ivacaftor	 metabolism	 after	 oral	 administration,	 occurs	
mainly	through	CYP3A4	resulting	in	two	major	metabolites	M1	and	M6,	with	1/6	and	
1/50	 of	 ivacaftor	 potency	 respectively(43).	 Consequently,	 Ivacaftor	 interacts	with	 all	
drugs	 heavily	 metabolized	 by	 CYP3A	 and	 thus,	 the	 coadministration	 of	 these	 drugs	
with	Ivacaftor	must	be	carefully	followed(48).		
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In	 clinical	 trials,	 in	 patients	 carrying	 in	 at	 least	 one	 allele	G551D	mutation,	 ivacaftor	
therapy	was	 associated	with	 improved	 forced	expiratory	 volume	 in	1	 second	 (FEV1),	
decreased	risk	of	pulmonary	exacerbation,	increased	quality	of	life,	improved	nutrition	
and	 a	 large	 correction	 in	 the	 typical	 CF	 elevated	 sweat	 chloride	 concentrations(49).	
These	ivacaftor	clinical	trials	findings	were	first	published	back	in	2011	in	NEJM	under	
the	 title	 “A	 CFTR	 potentiator	 in	 patients	 with	 cystic	 fibrosis	 and	 the	 G551D	
mutation”(49),	the	clinical	results	of	which	are	synthetized	in	figure	17.	
	
Figure	 17:	 Changes	 from	 baseline	 of	 different	 clinical	 parameters	 after	 48	 weeks	 of	 treatment	 with	 Ivacaftor	 or	
placebo.	This	clinical	trial	had	213	participants	and	Ivacaftor	was	studied	against	placebo	in	cystic	fibrosis	patients	
with	at	least	one	allele	for	G551D-CFTR	mutation.	Panel	A	shows	the	mean	improvement	in	forced	expiratory	volume	
(FEV1),	which	 ranged	 from	10.6%	to	12.5%.	Panel	B	 shows	 the	 time	 to	 the	 first	pulmonary	exacerbation,	 in	 those	
treated	with	Ivacaftor	the	risk	of	pulmonary	exacerbations	was	55%	lower.	Panel	C	displays	the	effect	that	Ivacaftor	
had	 on	 pulmonary	 function,	 measured	 with	 the	 standard	 Cystic	 Fibrosis	 Questionnaire	 (a	 100-point	 scale	 where	
higher	numbers	indicate	a	lower	effect	of	symptoms	on	the	patient’s	quality	of	life),	where	Ivacaftor	receiving	group	
scored	 8.6	 points	 higher.	 	 Panel	 D	 shows	 the	 change	 in	 weight	 which	 averaged	 a	 3.1kg	 gain	 with	 Ivacaftor.	
Additionally,	 in	 panels	 E&F,	 the	 change	 in	 sweat	 chloride,	 which	 reached	 values	 below	 what	 qualifies	 for	 	 CF	
diagnosis	60mMol,	ranging	from	a	-48	to	-54	mmol/L	improvement	in	the	group	treated	with	ivacaftor(49).		
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The	clinical	benefits	of	 Ivacaftor	were	 truly	 remarkable	 in	clinical	 trials.	Moreover,	 in	
the	extension	studies,	patients	previously	treated	with	Ivacaftor	displayed	a	sustained	
improvement	 in	 FEV1,	 weight	 and	 rate	 of	 pulmonary	 exacerbations	 for	 up	 to	 144	
weeks	of	treatment(50).	However,	there	was	a	lack	of	long-term	data	regarding	critical	
parameters	 such	 as	 mean	 survival	 improvement	 or	 the	 decline	 in	 pulmonary	
transplantation	rates. At	the	same	time,	authorities	noted	that	the	inclusion	criteria	for	
this	 clinical	 trial	 left	out	patients	with	predicted	<40%	FEV1,	 those	with	most	 severe	
pulmonary	 affection	 and	 that	 extrapulmonar	 variables	 such	 as	 the	 improvement	 in	
pancreatic	insufficiency	were	not	properly	addressed(44,51).		
	
Regardless	of	the	positive	clinical	impact	Ivacaftor	showed,	it	is	an	extremely	expensive	
treatment	 so	 healthcare	providers	 heavily	 discussed	 its	 inclusion	 in	 their	 services.	 In	
the	USA,	the	cost	of	the	medicine	per	year	of	treatment	is	294.000$(27)	although	the	
manufacturer	offers	both	a	co-pay	assistance	and	free	medicine	program	for	those	in	
most	 need	 who	 can’t	 afford	 the	 treatment(23).	 In	 the	 UK,	 the	 cost	 for	 Ivacaftor	 is	
182.625£	 per	 year.	 To	 asses	 it’s	 cost-effectiveness,	 the	 NHS	 designated	 a	 clinical	
commission	 to	 evaluate	 the	 drug	 and	 calculated	 the	 incremental	 cost	 effectiveness	
ratio	 (ICER)	 for	 Ivacaftor	 in	 comparison	 to	 current	 treatments	 which	 ranged	 from	
335.000£	per	QALY	(quality-adjusted	life	year)	in	the	most	optimistic	case	to	1.274M£	
in	a	more	conservative	scenario.	Although	the	cost	of	 Ivacaftor	fell	pretty	far	outside	
from	the	20-30.000£	per	QALY	threshold	typically	used	to	determine	cost-effectiveness	
in	the	NHS,	it	was	noted	that	the	ICER	for	the	optimistic	scenario	was	within	the	range	
of	 other	 ultra-orphan	medicines	 and	 thus	would	 include	 the	drug	 in	 its	 services	 and	
recommend	its	use	for	patients	with	eligible	mutations(29).		(59)	
	
Back	 home,	 in	 Spain,	 each	 Ivacaftor	 package	 containing	 58	 tablets	 costs	 18.720€,	
assuming	the	normal	posology	of	1	tablet	every	12	hours,	the	treatment	costs	a	total	
amount	 of	 244.028€	 per	 year.	 To	 illustrate	 just	 how	 expensive	 this	 treatment	 is	 in	
comparison	to	current	CF	treatments	that	also	reduce	FEV1,	figure	18	was	elaborated.		
	
Name	 Ivacaftor	 Hypertonic	serum	 Dornase	alfa	
Presentation	
Kalydeco®									
tablets		
Hyaneb®	
NaCl	7%	+	Hialuronic	0,1%	
Inh.	Sol.	30	bottles	
Pulmozymeâ															
2500	U/2,5	ml	
Inh.	Sol.	30	bottles	
Posology	 150	mg/12	h	 5	ml/12	h	 2500	U/24	h	
Change	in	FEV1		(%)	 10,5%	(week	24)	 3,2%	(week	48)	 5,8%	(week	24)	
Exacerbations	
reduction	(%)	
60%	(week	24)	 66%	(week	48)	 22%	(week	24)	
Annual	treatment	
cost	(€)	
244.028	 2.175	 7.227	
Figure	 18:	 Table	 comparing	 current	 treatments	 for	 cystic	 fibrosis	 patients	 that	 influence	 FEV1	 and	 pulmonary	
exacerbations.	Although	Ivacaftor	has	the	most	clinical	benefit,	the	cost	is	100x/35x	times	more	expensive	than	other	
alternatives.	To	elaborate	this	table	I	consulted	Genesis-SEFH	study	from	Andalucia	Pharmacotherapy	Group(52).	
Personalised	medicine	of	Cystic	fibrosis	|	Antoni	Cabré	Juan	
	
April	2017	 19	
	
Despite	the	prohibitive	cost	of	Ivacaftor,	in	Catalonia,	the	CatSalut	commission	“Consell	
Assessor	 de	 Tractaments	 Farmacològics	 d’Alta	 Complexitat	 (CATFAC)”	 recommended	
the	 drug	 as	 another	 form	 of	 treatment	 for	 CF	 if	 patients	 are	 carriers	 of	 one	 of	 the	
eligible	mutations	and	meet	all	this	specific	criteria(51):		
	
1. Patient’s	 sweat	 chlorine	 concentration	 is	 higher	 than	 60≥	 mmol/L	 or	 is	 a	
demonstrated	carrier	of	2	CF-causing	mutations.	
	
2. Phenotypic	 presence	 of	 sinopulmonary	 disease	 (with	 or	 without	 other	
manifestations	 characteristic	 of	 CF	 such	 as	 pancreatic	 insufficiency,	 sputum	
cultures	positive	for	pathogens	associated	with	CF	or	salt-wasting	syndrome).	
	
3. Patient’s	 predicted	 FEV1	 is	 ≥30%.	 This	 is	 because	 the	 scientific	 evidence	 in	
these	patients	with	predicted	FEV1	<40%	is	currently	lacking.	
	
Furthermore,	 all	 eligible	 patients	 for	 Ivacaftor	 treatment	 require	 an	 individualised	
doctor	 request	authorisation,	approved	by	 the	hospital	medical	director,	and	 further	
evaluation	 and	 authorisation,	 on	 a	 case	 by	 case	 basis,	 by	 CATFAC.	 If	 the	 request	 is	
approved,	 the	 treatment	 will	 require	 a	 specific	 follow	 up	 consistent	 in	 a	 periodic	
treatment	efficacy	evaluation,	with	FEV1	as	the	main	clinical	indicator,	in	months	3,	6,	
12,	 24…	 to	 properly	 assess	 patient	 response	 to	 treatment(53).	 The	 current	 doctor	
request	form	file	to	request	Ivacaftor	is	attached	in	Annex	1.	
	
To	determine	a	patient	 Ivacaftor	eligibility,	genetic	testing	of	CFTR	is	mandatory.	The	
current	 scheme	 recommended	 from	 Clinical	 Consortium	 of	 Pharmacogenetics	 for	
Ivacaftor	 treatment	 eligibility	 is	 presented	 in	 figure	 19.	 To	 do	 this	 genetic	
determination,	 there	 are	 currently	 84	 different	 laboratories	 offering	 186	 different	
clinical	 genetic	 tests	 registered	 in	 NCBI’s	 Genetic	 Testing	 Registry	 database.	 From	
those,	100	are	designed	to	sequence	the	entire	coding	region	of	CFTR	gene	and	74	are	
tests	 targeted	 for	 specific	 variants.	 In	 the	 same	 fashion,	 I’ll	 try	 to	 design	 my	 own	
genetic	test	targeted	for	all	current	Ivacaftor	eligible	CFTR	mutations.		
	
Figure	19:	Current	2017	recommended	
scheme	 for	 Ivacaftor	 eligibility.	 If	 a	
patient	is	proven	to	be	homozygous	for	
Δ508del,	 Ivacaftor	monotherapy	 is	 not	
recommended.	 However,	 if	 he	 is	
heterozygous	 for	 Δ508del	 and/or	
homozygous/heterozygous	 for	 any	 of	
the	 other	 mentioned	 SNP’s	 in	 the	
picture,	 ivacaftor	use	 is	 recommended.	
It	 is	 important	 to	 note	 that	 the	 drug	
costs	 over	 300.000$	 per	 year	 of	
treatment	 and	 currently	 under	 a	 strict	
case	 on	 case	 surveillance,	 so	 patient	
administration	of	 the	drug	 should	only	
be	 administered	 if	 eligibility	 criteria	 is	
met.	(Source:	PharmGKB(54))	
Personalised	medicine	of	Cystic	fibrosis	|	Antoni	Cabré	Juan	
	
April	2017	 20	
	
5.		Aims	
	
My	first	objective	in	this	project	is	to	make	a	bibliographic	research	about	the	current	
situation	 of	 personalised	 medicine	 to	 understand	 it’s	 impact	 in	 our	 future	 disease	
management.		
	
Secondly,	 I	 want	 to	 learn	 more	 about	 cystic	 fibrosis	 and	 Ivacaftor,	 understand	 the	
underlying	mechanisms	of	cystic	fibrosis	disease	and	try	to	shed	light	on	what	makes	
Ivacaftor	such	a	remarkable	advancement	in	cystic	fibrosis	therapy.		
	
Finally,	 I	 want	 to	 widen	 my	 practical	 knowledge	 in	 genomic	 tools	 available	 to	 the	
general	 public	 to	 improve	 my	 understanding	 of	 genomics.	 In	 order	 to	 achieve	 this	
objective,	 I	will	 study	CFTR	protein	 structure	and	design	a	genetic	 chip	 to	determine	
patient’s	eligibility	for	Ivacaftor.		
	
	
	
6.		Materials	and	methods		
	
I	 first	 researched	 about	 personalised	 medicine	 in	 university	 while	 completing	 an	
assignment	 of	 the	 subject	 Research	 in	 pharmaceutical	 biotechnology.	 I	 found	 the	
subject	 to	 be	particularly	 fascinating	 and	 consequently	 decided	 that	 the	 topic	 of	my	
TFG	would	revolve	around	this	subject.	To	achieve	this,	 I	will	conduct	a	much	deeper	
investigation	by	navigating	through	different	internet	databases.	
	
The	methodology	of	this	project	has	been	based	in	a	thorough	bibliographic	research	
and	the	subsequent	synthesis	of	the	articles	found.	To	do	so	I’ll	use	scientific	databases	
as	my	main	source	of	 information,	 searching	 for	 terms	such	as	“precision	medicine”,	
“cystic	fibrosis”	or	“CFTR	structure”,	which	mainly	will	be	PubMed	and	Web	Of	Science,	
available	at:		www.ncbi.nlm.nih.gov/pubmed	and	http://webofknowledge.com/.			
	
As	for	the	practical	experimental	part	of	this	project	at	the	Bioinformatic	level	in	silico,	
I	utilised	a	broader	 range	of	 resources	besides	bibliographic	 research.	To	study	CFTR	
structure	 I	 will	 use	 the	 data	 and	 tools	 found	 in	 Uniprot,	 Protein	 Data	 Bank	 (PDB),	
Phyre2	and	the	protein	visualisation	software	Pymol.	To	design	the	genetic	chip	to	test	
Ivacaftor	eligibility	I	will	rely	on	PharmGKB,	NCBI’s	dbSNP	and	SNPedia	databases.		
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7.	Results	and	discussion.	
	
		7.1	Structure,	functions	and	mutations	of	CFTR	
	
The	cystic	fibrosis	transmembrane	conductance	regulator	(CFTR),	first	characterized	in	
1989,	was	 the	 first	epithelial	 cell	 ion	channel	 to	have	 its	primary	 sequence	 structure	
determined.		Functionally	classified	as	an	intracellular	ATPase-gated	chloride	channel,	
CFTR	consists	of	1480	aminoacids	with	a	total	mass	of	170.000	Da(25).	Structurally,	it	is	
a	member	of	the	ATP	binding	cassette	(ABC)	transporters	superfamily	with	the	distinct	
functional	 difference	 of	 performing	 as	 an	 ion	 channel(55).	 CFTR	 structure	 can	 be	
divided	into	five	functionally	different	domains,	shown	in	figures	20,	21	&	22:	 
	
§ Two	 membrane-spanning	 domains	 (MSD1	 and	 MSD2),	 each	 composed	 of	 six	
transmembrane	segments	that	anchor	the	protein	to	the	plasmatic	membrane.		
	
§ Two	 nucleotide-binding	 domains	 (NBD1	 and	 NBD2)	 which	 together	 form	 a	
heterodimer	 complex	 that	 interacts	 with	 nucleotides,	 mainly	 ATP,	 to	 regulate	
chloride	channel	activity	by	regulating	the	opening	and	closing	of	the	MSD’s.		
	
§ The	regulatory	domain	 (R),	which	 is	unique	across	ABC	family,	 that	quantitatively	
regulates	channel	activity	while	activated.		
	
Figure	 20,	 21	 &	 22:	 Comparison	 of	 CFTR	 structure	
depicted	 in	 a	 cartoon	 image(21)	 and	 two	 far	 more	
realistic	 images	 of	 CFTR	 structure	 done	 by	 myself.	 To	
obtain	 these	 images	 I	 used	 Pymol	 software	 and	 the	
available	 data	 of	 dephosphorylated,	 ATP-free	 CFTR	
crystal	structure	obtained	in	a	2017,	not	yet	published,	
study	 (PDB	 5UAK(63)),	 Interestingly,	 in	 this	 protein	
conformation,	 we	 can	 fully	 appreciate	 both	MSD	 6	a-
helices	and	locate	the	R	domain.	To	identify	all	domains	
I	 used	 the	 aminoacidic	 sequences	 available	 in	 Uniprot	
(P13569(64)).	 The	exact	 domain	sequences	are:	MSD1:	
81-103+118-138+195-215+221-241+308-328+331-350;	
NBD1:	 433-584;	 R:	 590-831;	 MSD2:	 860-880+912-
932+991-1011+1014-1034+1103-1123+1129-1149.&	
NBD2:	1219-1382.		
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The	discrepancies	between	 the	 images	 I	 obtained	 from	 the	 crystal	 structure	of	CFTR	
and	the	cartoon	are	obvious.	The	cartoon,	which	 is	an	artistic	 impression,	represents	
the	conformation	of	CFTR	while	inserted	into	the	cytoplasmic	membrane.	On	the	other	
hand,	what	 is	seen	in	the	other	two	images	is	the	native	dephosphorylated,	ATP-free	
CFTR	conformation,	where	NBD	are	not	fully	dimerised.	Nevertheless,	the	5	regions	of	
CFTR	are	easily	identifiable	on	all	three	images.	
	
As	seen	in	the	cartoon	representation	and	in	the	sequences	annotated	in	the	figure’s	
description,	 following	 the	 direction	 of	 the	 protein	 primary	 structure,	 the	
transmembrane	 domains	 MSD1	 and	 MSD2	 consist	 of	 six	 regions	 arranged	 in	 line,	
separated	by	NBD1.	Next,	comes	the	regulatory	domain,	located	between	2	b-strands	
of	NBD1.	Finally,	NBD2	is	located	at	the	terminal	carboxyl	portion	of	the	protein.		
	
The	cellular	process	that	produces	mature	CFTR	is	complicated.	Once	CFTR	is	encoded,	
it	is	subsequently	integrated	into	the	endoplasmic	reticulum	membrane	where	it	is	N-
glycosylated	 by	 the	 addition	 of	 two	 glycosylated	 groups	 ,	 increasing	 its	weight	 from	
130	 to	 150	 kDa(58).	 With	 the	 help	 of	 chaperone	 molecules,	 such	 as	 Calnexin	 and	
Hsp70,	 the	 protein	 is	 folded,	 acquiring	 resistance	 to	 the	 cellular	 proteases	 and	
transported	to	the	Golgi	apparatus.	This	critical	step	is	apparently	very	inefficient	since	
only	25%	of	the	folded	protein	acquires	effective	resistance	towards	proteases,	making	
the	 transport	 to	 Golgi	 apparatus	 difficult.	 At	 this	 site,	 the	 glycosylated	 groups	 are	
modified	resulting	in	a	mature	170	kDa	protein	which	will	be	transported	to	the	apical	
membrane.	 Upon	 reaching	 the	 cell	 membrane,	 the	 protein	 enters	 a	 cycle	 of	
endocytosis	through	vesicles	and	is	recycled	back	to	the	cell	membrane.	Finally,	CFTR	
has	a	half-life	of	16	hours	and	is	degraded	in	the	cellular	cytoplasm	by	lysosomes(59).	
	
Different	studies	have	demonstrated	that	CFTR	transport	across	the	cell	membrane	is	
regulated	 by	 phosphorylation	 of	 Protein	 Kinase	 A	 (PKA)	 dependent	 of	 AMPc.	
Mechanistically,	 to	 activate	 CFTR	 channel	 a	 previous	 preparation	 is	 required,	 which	
consists	 in	the	phosphorylation	of	the	R	domain	and	subsequent	 interaction	with	the	
NBD	 domains	 and	with	 other	 parts	 of	 the	 protein.	 NBD1	 activation	 is	 necessary	 for	
channel	opening	and	is	the	determinant	of	the	closure	time.	Similarly,	NBD2	regulates	
the	opening	time	but	this	domain	is	not	required	to	initiate	channel	opening(60).		
	
Although	 CFTR	 was	 initially	 defined	 as	 a	 chlorine	 channel,	 the	 presence	 of	
phosphorylation	 points,	 as	 shown	 in	 figure	 20,	 coupled	 with	 the	 fact	 CFTR	 can	
hydrolyse	 ATP,	 indicate	 that	 the	 protein	 requires	 energy	 to	 perform	 its	 function.	
Therefore,	some	scientists	reclassified	CFTR	as	a	chlorine	active	transporter	instead.		
	
In	 addition	 to	 its	 function	 as	 a	 chlorine	 channel,	 CFTR	 participates	 in	 other	 cellular	
processes	 such	 as	 regulation	 of	 other	 ion	 channels,	 traffic	 of	 other	 transmembrane	
proteins	trough	the	cell	or	the	control	of	intracellular	pH(61).	
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To	 date,	 over	 2000	 CFTR	 mutations	 have	 been	 identified(25,26,41),	 the	 nature	 of	
which	 is	 very	 diverse	 as	 figure	 23	 demonstrates.	 These	 mutations	 can	 affect	 CFTR	
protein	 in	 several	 ways.	 Therefore,	 in	 order	 to	 seek	 better	 approaches	 to	 treat	 CF	
patients	and	maximize	therapeutic	effects,	CFTR	mutants	have	been	stratified	into	six	
groups	according	to	their	functional	deffect(55,57,61).	 In	figure	22	we	can	observe	in	
which	cellular	step	CFTR	dysfunction	occurs	in	relation	to	each	mutational	class.		
	
• Class	 I	mutations	 includes	 nonsense	mutations,	 frame	 shift	mutations	 and	 splice	
site	 mutations	 that	 produce	 premature	 termination	 signals.	 Consequently,	
unstable	 transcripts	 and/or	 aberrant	 proteins	 containing	 deleted	 amino	 acid	
sequences	 are	 formed.	 Such	 proteins	 are	 expected	 to	 be	 degraded	 rapidly,	
producing	a	net	effect	of	low	amount	of	CFTR	on	cell	surface.	
	
• Class	 II	 mutations	 display	 a	 trafficking	 problem	 caused	 by	 a	 misfolded	 or	
improperly	 processed	 CFTR	 protein.	 Under	 these	 circumstances,	 upon	 entrance	
into	 the	 endoplasmatic	 reticulum,	 most	 protein	 is	 degraded	 by	 cellular	 quality	
controls.	 A	 classic	 example	 of	 this	 group	 is	 the	 Δ508del	 mutation,	 a	 sequence	
deletion	 of	 an	 entire	 phenylalanine	 located	 at	 position	 508	 in	 CFTR	 protein.	
Δ508del	is	the	most	prevalent	mutation,	present,	in	at	least	in	one	allele,	in	86%	of	
patients	with	cystic	fibrosis(30).	
	
• Class	III	are	mutations	that	result	 in	a	full-length	CFTR	protein	that	has	difficulties	
with	 the	 activating/gating	 of	 the	 channel.	Most	 of	 these	mutations	 are	 found	 in	
NBD	and	interfere	with	the	binding	of	ATP	to	these	domains	or	with	the	stimulation	
of	 the	 channel	by	ATP,	 resulting	 in	 a	decreased	net	 chloride	 transport	 activity	of	
the	channel.	The	most	notable	mutation	of	 this	 class	 is	 the	G551D	mutation,	 the	
mutation	for	which	Ivacaftor	was	first	approved.			
Figure	23:	Schematic	unweighted	distribution	of	the	nature	of	
the	2015	mutations	described	in	the	cystic	fibrosis	mutation	
database(25).	
Figure	22:	The	six	mutational	classes	of	CFTR.	In	the	picture,	we	
can	 see	 the	 6	 classes	 of	 mutations	 and	 their	 respective	
explanations	with	the	location	of	the	problem	in	the	whole	CFTR	
protein	synthesis	and	incorporation	into	the	cell	surface	process	
(41).	(Image	extracted	from	CFTRScience(62))	
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• Class	 IV	mutations	have	affected	amino	acids	 in	MSD1,	 located	in	the	pore	of	the	
channel.	 Consequently,	 although	 the	 ATP	 binding	 and	 the	 quantity	 of	 CFTR	 on	
surface	 is	 normal,	 the	 proteins	 displays	 a	 defective	 conductance	 because	 the	
movement	of	chloride	through	the	pore	is	compromised.		
	
• Class	V	mutations	display	a	decreased	transcription	of	CFTR	gene,	often	caused	by	
a	splicing	defect	or	a	missense	mutation	in	CFTR	promoter.	The	net	result	is	a	very	
low	production	of	CFTR	and	thus,	these	mutations	cause	severe	forms	of	CF.	
	
• Class	 VI	 mutations	 produce	 unstable	 protein	 with	 low	 residence	 time	 due	 to	
premature	degradation.		
	
Although	the	heterogeneity	of	CFTR	mutations	is	extremely	complex	and	daunting,	as	
demonstrated	 in	 figure	24,	where	 the	 location	distribution	of	CFTR	mutations	across	
CFTR	gene	is	displayed,	a	few	select	mutations	account	for	most	CF	clinical	cases(55).	
More	importantly,	not	all	these	mutations	cause	cystic	fibrosis	and	from	those	that	do	
cause	CF,	not	all	of	them	do	so	in	the	same	degree	of	severity.	As	seen	in	figure	25,	the	
final	 phenotype	 of	 the	 patient	 is	 the	 result	 of	 the	 combination	 of	 both	 CFTR	 gene	
alleles.	Depending	on	the	exact	mutation	on	each	of	these	alleles	patients	will	display	a	
more	or	less	aggressive	form	of	cystic	fibrosis.	
	
	
However,	 the	genetic	 classification	discussed	above	 is	 impractical	 in	a	 clinical	 setting	
scenario.	Instead,	a	simpler	classification	is	used	to	improve	CF	patient	communication.	
Shown	 in	 figure	 25,	 CFTR	 mutations	 variants	 are	 classified	 into	 3	 groups	 (normal,	
residual	 activity	 or	 little	 to	 none	 activity).	 The	 CFTR	 activity	 value	 for	 each	 allele	 is	
proportional	to	the	total	number	of	CFTR	channels	 in	the	apical	membrane	weighted	
for	their	functionality	as	measured	by	their	conductance	and	probability	to	open.	Then,	
the	total	CFTR	activity	of	a	genotype	is	the	sum	of	both	alleles	intrinsic	activity.		
Figure	 24:	 Map	 displaying	 the	
mutations	 nature	 and	 location	
across	 the	27	exons,	26	 introns	
and	 other	 genetic	 regions	 that	
conform	 CFTR	 gene.	 (Image	
source:	 Cystic	 fibrosis	mutation	
database(25))	
Figure	 25:	 The	 phenotype	 of	 CF	
depends	on	the	genetic	 dotation	of	
both	 CFTR	 gene	 alleles.	 Depending	
on	the	exact	combination	of	alleles,	
patients	will	 display	a	more	or	 less	
aggressive	 form	 of	 CF.	 As	 seen	 in	
the	 image,	 patients	 with	 only	 one	
pathogenic	allele	might	only	display	
a	 mild	 form	 of	 CF	 whereas	
homozygous	 individuals	 for	 severe	
CF-causing	 mutations	 display	 seve	
CF	 phenotypes	 (Images	 source:		
CFTRScience	(62))	
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		7.2		Microarray	analysis	and	network	construction.	
	
Using	 the	 genomic	data	 from	differentially	 expressed	genes	between	normal	 and	CF	
human	 cells	 from	 a	 recent	 gene	 expression	 study	 where	 researchers	 compared	 the	
transcriptome	of	colon	epithelial	cells	between	healthy	participants	and	cystic	fibrosis	
patients	 I	 generated	 figure	 26.	 In	 this	 network	 of	 genes,	 each	 sphere	 represents	 a	
single	 gene	 with	 its	 size	 correlated	 with	 the	 magnitude	 of	 differential	 expression	
between	the	two	groups	and	each	connection	between	genes	(nodes)	accounts	for	a	
predicted	 protein-protein	 interaction.	 The	 quantity	 of	 nodes	 and	 the	 degree	 of	
clustering	 in	 these	 networks	 give	 scientists	 insight	 of	 the	 nature	 and	 severity	 of	
alteration	 that	 CF	 causes	 in	 gene	 expression.	 In	 this	 particular	 network,	 we	 can	
appreciate	2	clusters	of	proteins	connected	via	several	nodes.	As	demonstrated	in	the	
original	 study,	 the	protein	expressed	by	ACTB	gene	 (ß-actin),	 highlighted	 in	 red,	was	
identified	 as	 a	 CF	 genetic	modifiers	 and	 proven	 to	 interfere	 in	 several	 biomolecular	
processes,	indicating	it	might	be	an	interesting	target	for	future	drug	development.	(70)	
	
	
	
		7.3		Impact	of	G551D	mutation	
	
G551D,	displayed	in	figure	27,	is	a	single	nucleotide	polymorphism	(SNP)	consistent	in	
a	change	of	a	guanine	to	adenine	(G>A)	nucleotide	change	in	the	position	1784	of	exon	
11	of	CFTR	gene	which	effectively	changes	a	glycine	towards	an	aspartate	aminoacid	in	
position	 551	 of	 CFTR	 protein	 during	 translation(34,55).	 It	 is	 a	 class	 III	 mutation,	 a	
missense,	that	causes	a	severe	reduction	in	channel-open	probability	of	CFTR(54)	and	
is	 associated	 with	 a	 severe	 CF	 phenotype	 characterized	 for	 a	 marked	 pulmonary	
dysfunction	 and	 pancreatic	 insufficiency(64).	 Of	 the	 approximately	 70,000	 cases	 of	
cystic	fibrosis	worldwide,	3-4%	are	carriers	of	the	G551D	mutation,	making	it	the	third	
most	prevalent	CF	mutation(23,65).	The	allele	frequency	of	G551D	in	the	whole	world	
population	 is	 very	 low	 and	 highly	 varies	 with	 ethnicity/race,	 with	 values	 between	
0.02069%	among	caucasians	and	0.0013%	in	middle	eastern	populations(54).		
	
Figure	26:	 The	microarray	data	 I	 used	 to	 obtain	
this	network	was	extracted	from	the	study	“Gene	
expression	 in	 rectal	 epithelia	 of	 cystic	 fibrosis	
patients”(63),	 incorporated	 in	 the	 public	 GEO	
Datasets	 Catalogue	 (GSE15568	 entry).	 The	 data	
of	 this	study	was	submitted	to	GEOR2R	analysis,	
next,	 the	 top	 50	 genes	 from	 the	 pool	 of	 146	
genes	 list	 encountered,	 whose	 expression	 was	
significantly	different	between	the	2	groups,	was	
adjusted	 for	 P	 value,	 and	 was	 submitted	 to	 the	
online	 and	 public	 portal	 String	 where	 this	
network	was	generated.		
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To	 understand	 the	 changes	 that	 G551D	 causes	 in	 CFTR	 structure,	 we	 must	 first	
acknowledge	the	fact	that	when	both	NBD	domains	dimerise,	in	a	head	to	tail	manner,	
they	 form	 two	 ATP	 binding	 pockets	 (ATBP1	 and	 ATBP2),	 with	 the	 ATP	 molecules	
sandwiched	at	the	interface,	as	seen	before	in	figure	20.	The	aminoacids	that	conform	
both	pockets	are	key	signature	sequence	(regions	of	a	protein	very	conserved	among	
different	species)	of	CFTR.	Experiments	have	demonstrated	that	the	proper	formation	
of	both	ATBP	pockets	 in	 this	 interaction	 is	 critical	 for	 the	ATP-dependent	opening	of	
the	 CFTR	 channel(66,67).	 Moreover,	 changes	 in	 the	 aminoacids	 of	 these	 sequences	
have	a	much	lower	CFTR	ATP-mediated	activity	and	are	associated	with	CF(64).		
	
The	exact	aminoacids	that	conform	ATBP2	is	known	for	both	NBD1	and	NBD2	signature	
sequences,	 and	 Glycine551,	 located	 on	 NBD1’s	 ATBP2	 pocket,	 is	 one	 of	 them.	
Mechanistically,	 the	G551D	mutation	difficults	 the	ability	of	ATP	 to	bind	 into	ATBP2,	
completely	eliminating	the	ability	of	ATP	to	increase	the	opening	rate	of	CFTR(67).	To	
be	 precise,	 scientists	 have	 estimated	 that	 that	 mutant	 G551D-CFTR	 has	 a	 120	 fold	
decreased	conductance	in	comparison	to	wild	type	CFTR(64).		
	
To	study	the	 impact	of	G551D	mutation	on	CFTR	structure,	Phyre2	protein	modelling	
portal	was	consulted.	Introducing	G551D-CFTR	FASTA	sequence	the	website	predicted	
that	this	mutation	would	not	display	any	major	significant	changes	in	the	whole	CFTR	
structure	stability,	 in	 line	with	current	research(67).	Then,	using	Pymol	software,	and	
the	 experimental	 5UAK	 crystal	 structure	 data,	 I	 proceeded	 to	 locate	 and	 highlight	
where	Gly551	is	located,	shown	in	figure	28,	demonstrating	its	location	is	in	the	outer	
surface	 of	 the	 region	 of	 NBD1	 domain	 that	 dimerises	 with	 NBD2.	 This	 observation,	
taking	into	account	that	Gly551	participates	in	the	formation	of	ATBP2,	the	change	of	
this	 glycine	 for	 an	 aspartic	 acid,	 a	much	more	 acidic	 and	 bigger	 in	 volume	 residue,	
could	 easily	 difficult	 the	 formation	of	ATBP2	 and	 the	ATP	 interaction,	 explaining	 the	
dramatic	change	in	the	opening	rate	of	G551D-CFTR	seen	on	experiments.	
Figure	27:	Above	we	can	see	the	exact	location	of	this	mutation	using	NCBI’s	Geneview	navigation	tool.	On	the	right	
side	of	the	image,	in	pink	colors,	the	exon	11	exact	sequence	is	displayed	with	the	Gly551	aminoacid	circled	in	green.	
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Restoring	 the	 mutant	 CFTR	 dysfunction	 of	 G551D	 was	 thought	 to	 be	 possible	 by	
identifying	and	correcting	the	specific	cause	that	changes	total	CFTR	activity,	which	as	
explained	 before,	 depends	 on	 the	 total	 amount	 of	 CFTR	 available	 at	 the	 plasma	
membrane	 and	 their	 residence	 time	 once	 there;	 the	 gating,	 the	 probability	 of	 the	
channel	to	remain	open	in	the	presence	of	activation	stimuli;	the	conductance	of	the	
channel	and	finally,	the	ability	of	ions	to	permeate	open	CFTR	channel.		
	
However,	 as	easy	as	 it	 sounds,	 strategies	aiming	 to	 restore	 function	 to	mutant	CFTR	
date	back	 to	 the	90s.	Both	pharmacological	 and	nonpharmacological	 strategies	have	
been	 designed.	 Notable	 examples	 include	 treatment	 of	 cells	 with	 co-chaperone	
molecules,	 suppression	 of	 premature	 termination	 codons	 with	 aminoglycosides	 and	
drug	 based	 treatments	 with	 Curcumin,	 Misglustat	 or	 Ataluren(22).	 The	 latter,	 is	
currently	in	phase	III	clinical	trials(26).	
	
Until	 Ivacaftor,	 first	 approved	 only	 for	 G551D	 mutation	 on	 2012,	 there	 wasn’t	
commercialised	 any	 agent	 capable	 of	 reverting	mutant	 CFTR	 dysfunction.	 Therefore,	
Ivacaftor	was	a	huge	breakthrough	in	CF	therapy	and	a	ray	of	hope	for	cystic	fibrosis	
patients	 as	 this	 first-in-class	 drug,	 aimed	 only	 for	 4%	 of	 CF	 patients,	 could	 lead	 to	
future	treatments	with	greater	scope	of	mutations.	This	was	the	case	because	in	2015,	
the	launch	of	Orkambi	(Ivacaftor/Lumacaftor),	is	able	to	treat	CF	patients	homozygotic	
for	Δ508del.	The	development	of	 this	drug	wouldn’t	have	been	possible	without	 the	
previous	CF	knowledge	acquired	throughout	the	development	of	Ivacaftor.	
	
In	the	near	future,	inhaled	gene	therapy	has	been	proposed	as	the	final	cure	of	cystic	
fibrosis	as	it	could	completely	revert	disease.	To	date,	over	25	clinical	trials	have	been	
conducted	with	both	 viral	 and	non-viral	 gene	 vectors	 trying	 to	 insert	 in	 the	 genome	
WT-CFTR	and	all	of	them	failed	to	show	sustained	clinical	benefits(68).	However,	with	
the	recent	developments	in	CRISPR/Cas9	technology,	the	possibility	to	cure	any	type	of	
cystic	 fibrosis	mutation	 is	 gaining	 strength.	With	 this	 technique,	 the	 scenario	where	
embryos	 diagnosed	 with	 CF	 are	 routinely	 genetically	 corrected	 to	 prevent	 the	
development	of	CF	might	not	be	science-fiction	anymore.		
Figure	28:	To	obtain	this	image	I	used	
Pymol	surface	display	and	the	crystal	
structure	 of	 CFTR	 (PDB	 5UAK(63)).	 I	
located	 Gly551	 and	 subsequently,	
disabled	 surface	 display	 for	
aminoacids	within	 6Å	diameter	 from	
Gly551.	 In	 the	 image	 we	 can	 fully	
appreciate	 how	 Gly551	 is	 located	 in	
the	 outermost	 part	 of	 NBD1	 (green)	
that	 faces	 NBD2	 (pink),	 supporting	
the	 hypothesis	 that	 G551D	mutation	
changes	 ATBP2	 pocket	 structure	
when	both	NBD	dimerise.	
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7.4		Pharmacogenetic	chip	for	Ivacaftor	eligibility	
	
In	 order	 to	 be	 able	 to	 design	 the	 probes	 to	 test	 Ivacaftor	 eligibility	 I	 consulted	 the	
current	EMA	approved	eligible	mutations(48).	The	methodology	I	used,	after	knowing	
which	mutations	the	test	should	account	for,	consisted	of	a	PharmGKB	research	of	said	
mutations	 to	obtain	 their	 respective	 reference	sequence.	After	 that,	 I	 retrieved	 from	
dbSNP	NCBI’s	database	the	fragments	of	the	open	reading	frame	consensus	sequence	
of	CFTR	gene	for	each	mutation.	Then,	the	next	step	was	the	identification	of	the	exact	
SNP	base	variation(s)	from	the	consensus	sequence,	marked	in	red	in	figure	29.	Lastly,	I	
proceeded	to	obtain	the	complementary	sequences	of	these	consensus	sequences	to	
finally	 obtain	 the	 final	 DNA	 molecule	 that	 will	 be	 used	 as	 probes	 and,	 if	 desired,	
implemented	 in	 an	 Amplichip	 test	 to	 easily	 assess	 cystic	 fibrosis	 genotype	 and	 use	
Ivacaftor	treatment	when	necessary.	
	
	
Figure	29:	 To	determine	 if	 a	patient	 is	 homozygous	 for	a	 certain	 variant,	 say	 [G551D/G551D],	 hybridization	must	
only	occur	only	with	the	G551D	pathogenic	probe	(light	reddish).	On	the	other	hand,	a	heterozygous	genotype	such	
as	[Δ508/S1255P]	would	display	in	the	assay	with	hybridization	occuring	in	both	pathogenic	probes.	If	no	pathogenic	
probe	hybridizes	 in	 the	 test,	patient	might	 still	 be	 carrier	of	other	mutations	CF-causing	mutations.	 The	predicted	
prevalence	 in	 the	 table	 is	calculated	 from	the	 frequency	seen	 in	CFTR2	registry	database	which	consists	of	a	 total	
amount	of	88.664	registered	cystic	fibrosis	patients(34).		
Mutation	
Prevalence	
in	CF	(34)	
SNP		
Ref.	Seq.	
Probe	sequence	to	introduce	to	Amplichip	
If	probe	
hybridizes,	
G178R	 0.059%	 rs80282562	
TTCCTCTGATTGTTCAACAGTTTATGAATAAAATAGATCTT	 G178R	present	
TTCCTCTGATTGTTCAACAGCTTATGAATAAAATAGATCTT	 G178R	not	present	
S549N	 0.144%	 rs121908755	
TCTTCCACCTTAGTGTGACTTACCTCCAGTTGCTCGTTCTT	 S549N	present	
TCTTCCACCTTAGTGTGACTCACCTCCAGTTGCTCGTTCTT	 S549N	not	present	
S549R	 0.050%	
rs121909005	
CTTCCACCTTAGTGTGACTCCCCTCCAGTTGCTCGTTCTTA	 549R	present	
CTTCCACCTTAGTGTGACTCACCTCCAGTTGCTCGTTCTTA	 549R	not	present	
rs121908757	
CTCTTCCACCTTAGTGTGACGCACCTCCAGTTGCTCGTTCT	 549R	present	
CTCTTCCACCTTAGTGTGACTCACCTCCAGTTGCTCGTTCT	 549R	not	present	
G551D	 2.111%	 rs75527207	
CACCTTAGTGTGACTCACCTCTAGTTGCTCGTTCTTAAAGA	 G551D	present	
CACCTTAGTGTGACTCACCTCCAGTTGCTCGTTCTTAAAGA	 G551D	not	present	
G551S	 0.013%	 rs121909013	
CACCTTAGTGTGACTCACCTTCAGTTGCTCGTTCTTAAAGA	 G551S	present	
CACCTTAGTGTGACTCACCTCCAGTTGCTCGTTCTTAAAGA	 G551S	not	present	
G1244E	 0.075%	 rs267606723	
GAATATCCACCCGGAGAACCTTTCTTGACCTAGTCCCTTCT	 G1244E	present	
GAATATCCACCCGGAGAACCATTCTTGACCTAGTCCCTTCT	 G1244E	present	
GAATATCCACCCGGAGAACCCTTCTTGACCTAGTCCCTTCT	 G1244E	not	present	
G1349D	 0.016%	 rs193922525	
CCCGACACAGGATTCGGTACTGGTGTTCGTCAACTACACGA	 G1349D	present	
CCCGACACAGGATTCGGTACCGGTGTTCGTCAACTACACGA	 G1349D	not	present	
S1251N	 0.085%	 rs74503330	
TTCTTGACCTAGTCCCTTCTTATGAAACAATAGTCGAAAAA	 S1251N	present	
TTCTTGACCTAGTCCCTTCTCATGAAACAATAGTCGAAAAA	 S1251N	not	present	
S1255P	 0.007%	 rs121909041	
GTCCCTTCTCATGAAACAATGGTCGAAAAAACTCTGATGAC	 S1255P	not	present	
GTCCCTTCTCATGAAACAATAGTCGAAAAAACTCTGATGAC	 S1255P	not	present	
R117H	 1.310%	 rs78655421	
GGGCCTATTGTTCCTCCTTGTGAGATAGCGCTAAATAGATC	 R117H	present	
GGGCCTATTGTTCCTCCTTGGGAGATAGCGCTAAATAGATC	 R117H	present	
GGGCCTATTGTTCCTCCTTGAGAGATAGCGCTAAATAGATC	 R117H	present	
GGGCCTATTGTTCCTCCTTGCGAGATAGCGCTAAATAGATC	 R117H	not	present	
Δ508del	 69.856%	
rs113993960	
TGGTAATTTCTTTTATAGTA[]ACCACAAAGGATACTACTTA	 Δ508del	present	
TGGTAATTTCTTTTATAGTAGAAACCACAAAGGATACTACTT	 Δ508del	not	present	
rs199826652	
GTGGTAATTTCTTTTATAGT[]AACCACAAAGGATACTACTT	 Δ508del	present	
GTGGTAATTTCTTTTATAGTAGAAACCACAAAGGATACTACT	 Δ508del	not	present	
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A	minimum	of	16	pathogenic	probes,	highlighted	in	red,	are	needed	to	determine	the	
13	 mutations	 eligible	 for	 Ivacaftor	 treatment.	 On	 the	 other	 hand,	 for	 the	 not	
pathogenic	ones,	highlighted	 in	green,	a	minimum	of	9	probes	are	 required	because	
S549N,	 S549R,	 G551D&G551S	 and	 S1251N&S1255P	 could	 share	 the	 same	 none	
pathogenic	probes.	In	total,	25	unique	probes	should	be	inserted	in	the	Amplichip	test.	
	
The	Amplichip	P450	test	is	a	patented	clinical	microarray-based	genetic	test	developed	
by	Roche	and	approved	for	use	by	FDA	in	2004	that	tests	for	34	CYP2D6	variants(69).	
The	methodology	to	do	the	test	is	quite	simple,	firstly,	starting	from	a	blood	or	saliva	
sample,	 the	 patient’s	 DNA	 is	 extracted.	 Then,	 the	 CFTR	 gene	 is	 amplified	 by	 PCR	
techniques,	 fragmented	 and	 labelled.	 The	 next	 step	 is	 a	 hybridization	 of	 the	 PCR	
products	 on	 to	 the	 Amplichip	 microarray	 that	 contains	 all	 the	 predefined	 probes.	
Finally,	the	chip	is	scanned	and	the	data	is	analysed	to	determine	patients	genotype.	
	
With	all	the	information	given	in	figure	29	we	could	design	our	test	and	implement	it	in	
an	Amplichip	test.	With	it	we	could	accurately	diagnose	11	CFTR	mutations	and	easily	
determine	patient’s	eligibility	for	Ivacaftor	treatment.	
	
However,	 in	practice,	patients	 first	 should	 test	 for	Δ508del	and	only	proceed	 further	
with	my	pharmacogenetic	chip	if	not	found	Δ508del/	Δ508del	or	Δ508del/WT	because	
Amplichip	tests	are	quite	expensive,	with	a	price	between	600-1200€.	This	preliminary	
mutation	 test	 is	 available	 all	 over	 the	 world	 and	 easily	 identifies	 CF	 patients	 with	
genotypes	 Δ508del/Δ508del	 or	 WT/Δ508del,	 which	 are	 not	 candidate	 for	 Ivacaftor.	
Particularly,	 in	 Spain,	 as	 seen	 in	 figure	 30,	 Imegen,	 a	 genetics	 laboratory	 located	 at	
Valencia,	commercialises	this	test	for	104€	with	an	estimated	delivery	of	results	of	20	
days.	Interestingly,	the	very	same	laboratory	also	offers	a	CFTR	genetic	tool	kit	aimed	
at	researchers	and	clinicians	to	carry	on	a	molecular	genetic	analysis	of	 the	full	CFTR	
gene	via	PCR	and	posterior	Sanger	sequencing.	
	
Figure	 30:	 On	 the	 right,	 Imegen’s	 kit	 to	 sequence	 by	 capillary	
electrophoresis	 (Sanger	sequencing)	the	whole	CFTR	gene.	This	kit	
includes	 all	 needed	 reagents	 to	 perform	 the	 amplification	 of	 all	
coding	 regions	 and	 the	 primers	 for	 the	 sequencing	 reactions.	 On	
the	 bottom,	 the	 same	 company	 offers	 different	 test	 services	 for	
CFTR	 gene.	 From	 complete	 CFTR	 sequencing	 to	 tests	 targeted	 for	
specific	variants,	circled	in	red,	the	Δ508del	mutation	test.	
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8.	Conclusions	
	
• With	 the	 current	 advancements	 in	 bioinformatics	 and	 genomic	 technologies,	
personalised	medicine	has	the	potential	to	explore	the	causes	of	the	variability	 in	
drug	 response,	 improving	 efficacy	 of	 treatments	 and	 preventing	 adverse	 drug	
events.	Consequently,	regulatory	bodies	all	over	the	world	are	developing	several	
policies	to	promote	its	implementation	in	modern	healthcare	systems.	
	
• Despite	 having	 been	 studied	 for	many	 decades	 and	 being	 a	monogenic	 disease,	
cystic	 fibrosis	 is	 a	 very	 complex,	 chronic,	 life-threatening	 disorder	 the	 clinical	
management	 of	 which	 still	 has	 room	 for	 improvement.	 In	 the	 future,	 it	 will	 be	
important	to	develop	drugs	that	affect	whole	functional	classes	of	CFTR	mutations	
rather	than	specific	alleles	to	expand	treatment	to	all	patients	with	cystic	fibrosis.	
	
• Even	 though	cystic	 fibrosis	 is	 the	most	 common	and	widespread	genetic	disease,	
the	exact	reason	to	explain	its	prevalence	has	not	been	fully	elucidated	yet.	
	
• The	 enormous	 variability	 in	 cystic	 fibrosis	 phenotypes	 is	 caused	 by	 several	
confounding	factors.	Firstly,	the	variety	in	genotypes	is	immense	because	there	are	
described	over	2000	different	mutations	all	of	them	causing	different	alterations	in	
CFTR	function;	secondly,	CFTR	is	heavily	pleiotropic,	it	is	expressed	in	many	tissues	
and	 can	 alter	 several	 systems	 in	 various	 degrees	 all	 at	 once;	 finally,	 there	 are	
described	several	genetic	modifiers	locus	in	the	genome	capable	of	modifying	the	
disease	course.	Therefore,	 individualising	patient	care,	personalising	CF	medicine,	
can	have	a	huge	impact	in	the	management	of	cystic	fibrosis.	
	
• The	 total	 CFTR	 activity	 is	 determined	 by	 CFTR	 genotype	 which	 results	 from	 the	
specific	 combination	 of	 variants	 present	 on	 both	 alleles.	 Each	 mutation	 has	 an	
intrinsic	CFTR	activity	value	proportional	 to	the	total	number	of	CFTR	channels	 in	
the	membrane	weighted	for	their	functionality	as	measured	by	their	conductance	
and	probability	to	open.	The	sum	of	both	allele’s	value	give	us	a	total	CFTR	activity.	
	
• The	G551D	mutation	takes	places	in	NBD1	and	this	single	aminoacid	change	affects	
the	 formation	of	ATBP2	when	both	NBD	dimerise.	As	a	 result,	 the	ATP-mediated	
conductance	of	CFTR	decreases	heavily.	
	
• Ivacaftor	works	by	 increasing	the	probability	of	CFTR	channel	to	remain	activated	
once	opened.	Although	it	was	first	commercialised	for	G551D	mutation,	today	it	is	
approved	for	another	9	mutations.	
	
• To	 design	 an	 Amplichip	 to	 asses	 Ivacaftor	 treatment	 eligibility,	 25	 unique	 DNA	
probes	are	necessary	to	properly	asses	all	candidate	mutations.	
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Annex	1	
	
The	current	official	doctor	request	form	file	to	request	Ivacaftor	treatment	in	Catalonia	
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